From ASCA breakthrough in Crohn's disease and Candida albicans research to thirty years of investigations about their meaning in human health

Boualem Sendid, Marjorie Cornu, Camille Cordier, Julie Bouckaert, Jean Frederic Colombel, Daniel Poulain

▶ **To cite this version:**

Boualem Sendid, Marjorie Cornu, Camille Cordier, Julie Bouckaert, Jean Frederic Colombel, et al.. From ASCA breakthrough in Crohn's disease and Candida albicans research to thirty years of investigations about their meaning in human health. Autoimmunity Reviews, 2024, Autoimmunity Reviews, 23 (2), pp.103486. 10.1016/j.autrev.2023.103486 . hal-04490346

HAL Id: hal-04490346

https://hal.univ-lille.fr/hal-04490346v1

Submitted on 5 Mar 2024

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Distributed under a Creative Commons Attribution - NonCommercial - NoDerivatives 4.0 International License

Autoimmunity Reviews 23 (2024) 103486

Contents lists available at ScienceDirect

Autoimmunity Reviews

journal homepage: www.elsevier.com/locate/autrev

From ASCA breakthrough in Crohn's disease and *Candida albicans* research to thirty years of investigations about their meaning in human health

Boualem Sendid [a,b,*], Marjorie Cornu [a,b], Camille Cordier [a,b], Julie Bouckaert [c], Jean Frederic Colombel [d], Daniel Poulain [a,*]

[a] INSERM U1285, CNRS UMR 8576, Glycobiology in Fungal Pathogenesis and Clinical Applications, Université de Lille, F-59000 Lille, France
[b] Pôle de Biologie-Pathologie-Génétique, Institut de Microbiologie, Service de Parasitologie-Mycologie, CHU Lille, F-59000 Lille, France
[c] CNRS UMR 8576, Computational Molecular Systems Biology, Université de Lille, F-59000 Lille, France
[d] Department of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA

ARTICLE INFO

Keywords:
Anti-*Saccharomyces cerevisiae* antibodies (ASCA)
Candida albicans
Crohn's disease
Mannosylation
Pathophysiology
Autoimmune disease

ABSTRACT

Anti-*Saccharomyces cerevisiae* antibodies (ASCA) are human antibodies that can be detected using an enzyme-linked immunosorbent assay involving a mannose polymer (mannan) extracted from the cell wall of the yeast *S. cerevisiae*. The ASCA test was developed in 1993 with the aim of differentiating the serological response in two forms of inflammatory bowel disease (IBD), Crohn's disease and ulcerative colitis. The test, which is based on the detection of anti-oligomannosidic antibodies, has been extensively performed worldwide and there have been hundreds of publications on ASCA. The earlier studies concerned the initial diagnostic indications of ASCA and investigations then extended to many human diseases, generally in association with studies on intestinal microorganisms and the interaction of the micro-mycobiome with the immune system. The more information accumulates, the more the mystery of the meaning of ASCA deepens. Many fundamental questions remain unanswered. These questions concern the heterogeneity of ASCA, the mechanisms of their generation and persistence, the existence of self-antigens, and the relationship between ASCA and inflammation and autoimmunity. This review aims to discuss the gray areas concerning the origin of ASCA from an analysis of the literature. Structured around glycobiology and the mannosylated antigens of *S. cerevisiae* and *Candida albicans*, this review will address these questions and will try to clarify some lines of thought. The importance of the questions relating to the pathophysiological significance of ASCA goes far beyond IBD, even though these diseases remain the preferred models for their understanding.

1. Introduction

Among the biological tests that have contributed to the diagnosis of inflammatory bowel diseases (IBD), the enzyme-linked immunosorbent assay (ELISA) developed by us in 1993 [1] and published in 1996 [2], and named ASCA (anti-*Saccharomyces cerevisiae* antibodies) in 1999 [3], was a pioneer. For the past 30 years, it has remained a robust test as a marker of Crohn's disease (CD) in terms of prediction and prognosis.

Historically, this test was derived from pioneering observations made after immunofluorescence studies on different strains of *S. cerevisiae* by Mckenzie et al., and then by us [2,4]. Its transition to an automatable ELISA format, which is adaptable [2] to a large number of patients, has generated significant medical and commercial interest [5–7]. On a fundamental level, the demonstration of the existence of anti-yeast antibodies that are markers of IBD opened up investigations into the role of the mycobiota in human disease [8–11]. Our early studies incriminated the yeast *Candida albicans*, which is a major component of the mycobiota, capable of colonizing all segments of the human digestive tract, as well as a major opportunistic pathogen whose dissemination from the gut is a regular cause of fatal invasive fungal infections [12].

The current review was carried out for three main reasons: (i) ASCA have now been detected in a large number of human diseases; (ii) studies on the mycobiota have increased considerably and have been refined, resulting in them becoming more in line with traditional methods of microbiology; (iii) fundamental studies on the interactions between *C. albicans* and the digestive tract have reached an unparalleled level of scientific quality.

* Corresponding authors at: Faculté de Médecine, Pôle Recherche, 1 Place Verdun, 59045 Lille CEDEX, France.
E-mail addresses: boualem.sendid@univ-lille.fr (B. Sendid), daniel.poulain@univ-lille.fr (D. Poulain).

https://doi.org/10.1016/j.autrev.2023.103486
Received 9 November 2023; Accepted 23 November 2023
Available online 30 November 2023
1568-9972/© 2023 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

In this review, we discuss the main findings of this vast amount of research, which raises the question of the origin of ASCA, the regulation of ASCA synthesis, and ultimately, the meaning of ASCA in human health.

2. ASCA test for Crohn's disease

2.1. Initial contribution to the differential diagnosis of IBD, to patient stratification, and prognosis

This area of research originated from a gastroenterologist community who was interested in ASCA as a biomarker of CD. Thirty years later, ASCA remain the strongest and most studied biomarker in this setting. At the beginning of this review on the meaning of ASCA, we first need to briefly address the clinico-epidemiological framework established about ASCA *i.e.*, the differential diagnosis of IBD, patient stratification, prognosis, and prediction of CD. We do not intend to be exhaustive as this has already been the subject of excellent reviews and meta-analyses [13,14].

ASCA first contributed to IBD management by differentiating CD from ulcerative colitis (UC). Assays for ASCA in CD patients show a prevalence ranging from 50 to 60% depending on the geographic and ethnic origin of the patients, in contrast to 0–6% in the general population [15,16]. The combined detection of ASCA and perinuclear-antineutrophil cytoplasmic antibodies (pANCA) differentiates CD from UC [3,17–19], with a sensitivity ranging from 30 to 64%, a specificity of >90%, and positive predictive value ranging from 77 to 96% [20]. This discrimination was shown to extend to indeterminate colitis [21]. Subsequently, additional fungal biomarkers including antilaminaribioside antibodies (ALCA) and antichitobioside antibodies (ACCA) were shown to be positive in 26% of ASCA-negative CD patients [20].

It was also discovered that ASCA positivity relates to early CD development and concerns ileal forms requiring surgery [3,22–24]. Similarly, single or multiple detection of antimicrobial antibody markers including ASCA, as well as the amplitude of the antibody response, were independently linked to a severe disease phenotype [14,25–30]. This was confirmed by Vasiliauskas et al. using multiple regression analyses, notably for fibro-stenosing and internal penetrating disease behaviors [24–26,31]. Other studies have reported that CD patients with serological positivity for ASCA more frequently present with an ileal or ileocolonic location [29], but these antibodies do not differentiate stricturing and non-stricturing forms [32]. In a meta-analysis, Ricciuto et al. reported that 5/8 studies showed a significant association between ASCA status and surgery. The pooled Odds ratios (OR) for the five studies was 2.31, while the pooled hazard ratio (HR) for four of these studies also showed a significantly increased risk of surgery (HR = 2.59) [33].

In agreement with the association between ASCA and the early development of CD, the sensitivity of ASCA is higher (50–86%) in pediatric patients with suspected IBD, with good specificity (85–95%), making ASCA more useful for the screening of CD in this patient subgroup [17,34–36]. Consistent with their profile in adults, ASCA have been shown to be independently associated with a complicated phenotype, ileal involvement, and the need for surgical resection [27].

With the advent of "biologics" it became obvious that as ASCA were associated with severe forms of CD, the detection of ASCA should initiate their early use. A prospective study in a newly-diagnosed, treatment-naive cohort showed that if ASCA were positive at baseline, CD patients had an almost 9-times higher odds of receiving early TNF blocker treatment compared to those who were ASCA negative, with a probability of 70% (OR = 8.8 [95%CI: 2.0–37.7]; $p < 0.01$) [37]. Another study reported more aggressive features in seropositive patients, such as more extensive involvement and moderate to severe disease [38]; interestingly, these severe ASCA-positive forms had comparatively lower relapse rates than patients with negative ASCA titers when anti-TNF biological therapy was introduced early.

In addition to their contribution to the clinical management of CD, ASCA have contributed to unravelling epidemiological clues about the disease. The first is familial aggregation. In our initial CD family study, ASCA were detected in 35/51 (69%) patients with CD and in 13/66 (20%) of healthy relatives vs. 1/63 controls ($p < 0.001$) [16]. The presence of ASCA in healthy relatives was observed in 12/20 families and was not restricted to a few particular multiplex families [15]. The prevalence of ASCA in relatives did not depend on the ASCA status of affected members. These findings were confirmed by Seibold et al., who found ASCA in 48 (25%) of 193 healthy first-degree relatives [39] as well as in a large series of Belgian families having one or more than two affected members [40]. Moreover, a study focusing on 98 twin pairs with IBD showed a high degree of concordance between ASCA titers in monozygotic twin pairs with CD suggesting that the level of increase is genetically determined [41].

In parallel, a large number of studies have revealed a unique characteristic of ASCA positivity in CD, namely their life-long stability. ASCA-positive levels appear to be stable in CD patients irrespective of medical or surgical treatment [3,26,40,42,43]. This characteristic is discussed further below.

In the line with these characteristics, another significant finding was that ASCA pre-existed the development of CD. This fact was established after investigations on serum repositories from conscripts archived before a diagnosis of IBD. They demonstrated that ASCA pre-exist CD for as long as 3–5 years before clinical diagnosis of the disease [44,45].

In conclusion, although the ASCA test is not recognized as a diagnostic test for CD by some gastroenterologists, who point to its non-optimal sensitivity, its contribution to the early diagnosis of CD should not be overlooked insofar as a recent meta-analysis showed that all complications arise from the late diagnosis of CD [46].

3. The basic question of the ASCA epitope(s)

In contrast to the thousands of papers concerning the meaning of ASCA, little attention has been paid to the nature of the epitope(s) recognized by these antibodies, a basic question which, if unsolved, precludes any rational interpretation.

3.1. Preliminary identification of the major ASCA epitope

Following the early development of an ELISA test to detect human antibodies directed against *S. cerevisiae* mannan [2] (later designated the ASCA test [3]), we identified a tetramannoside composed of α-1,2 linked mannose with an α-1,3 mannose at the non-reducing end among the complex *S. cerevisiae* mannan repertoire as the major epitope supporting the human response during CD (see Fig. 1). This identification was confirmed unambiguously by another independent study ascribing the antigenic activity of the original high molecular weight mannan to terminal Man α-1,3 Man α-1,2 [47]. Subsequent studies using synthetic analogues of the tri- and tetramannoside epitopes showed that such constructions were able to detect antibodies in patients with CD [48,49] and conversely to elicit animal antibodies reacting with the ASCA test [50].

3.2. The question is much more complex

At the start of the investigations on anti-yeast antibodies in CD [51], the methods used consisted of the detection of antibodies against whole yeast cells by immunofluorescence, agglutination, or after direct coating on microtiter plates. In a remarkable pioneering study, McKenzie et al. showed that all *S. cerevisiae* and *C. albicans* strains tested varied in their ability to bind patients' antibodies and confirmed this antigenic heterogeneity by cross-absorption experiments [4]. Later molecular investigations on yeast mannan antigens mainly concerned *S. cerevisiae* strains whose cells were selected for being the most reactive against patients' sera (i.e., Su1 strain for our study [2] and Sc500 strain for the study of Barnes et al. [47] in which the ASCA major epitope was over-



Fig. 1. Graphical abstract: inter-related traits of ASCA discovered over time.
Representation of the evolution of knowledge in the 3 fields involved in scientific and medical research concerning ASCA (Vertical panels). The two major evolution of medical concepts and microbiological methods are shown laterally. In each of these panels, rectangles represent the successive achievements over 30 years with immunology being at the interface.

represented).

Other investigations on *S. cerevisiae* antigens revealed reactivity with the carbohydrate moiety of a 200 kDa mannoprotein of *S. cerevisiae*, but the existence of the major mannan ASCA epitope on this antigen was not determined. This would have made sense bearing in mind the ability of yeasts to express a given epitope on the carbohydrate moieties of different molecules, either glycoproteins or even glycolipids [52–54]. A monoclonal antibody against *S. cerevisiae* GP 200 carbohydrate moiety was raised by the same group [55,56], but it is unknown if it reacts with mannan.

When synthetic ASCA epitopes were used to detect antibodies in a large multicenter study, including 1365 sera, the specificity for CD was similar to the ASCA test [49], although, as could be expected for a non-microbial native product, the sensitivity was lower (38% vs. 55%). Surprisingly, in spite of this lower sensitivity, the synthetic epitope allowed the detection of a substantial number of CD patients (24%), mostly with colonic involvement, who were negative for ASCA and/or any associated serological markers. This agrees with the reactivity of so-called AMCA (anti-mannoside carbohydrate antibodies), a dimannoside corresponding to the non-reducing terminal end of the ASCA epitope which is observed in some CD-negative ASCA patients [57]. Regarding native "natural" yeast antigens, a similar conclusion about complementation was reached when the ASCA responses of CD patients from North Africa were investigated using an in-home test involving mannan from a strain designated W303 and our original ASCA test with Su1 mannan. In this case, the combination of tests resulted in a slight decrease in specificity to 80%, but an impressive sensitivity of 80% for differentiating CD from UC [58].

From a fundamental point of view, these studies demonstrate the considerable heterogeneity of the ASCA response in humans, revealed by comparison of various commercially available tests [59,60] but which has never been explored about complementation for diagnostic purposes or, importantly enough, addressed to understand the meaning of the ASCA response. Thus, although the oligomannose sequences composed of α-1,3 Man at the non-reducing end of α-1,2 Man chains is undoubtedly highly reactive with sera from CD patients, the human anti-mannose ASCA response comprises a wide variety of more or less structurally related motifs that remain to be elucidated, as well as their clinical significance.

4. *C. albicans* is undoubtedly an ASCA immunogen

4.1. Experimental and clinical evidence

With regard to the large and increasing number of papers and reviews on the mycobiota, which suggest a role for *C. albicans* in CD [61], very few papers have addressed this question from a molecular point of view.

A number of concordant scientific facts have been established. Experimentally, *C. albicans* was shown to generate ASCA when it was

used to infect rabbits by the intravenous route [62], or when it thrives in the guts of mice with dextran sulphate sodium (DSS)-induced inflammation [63]. In humans suffering from systemic candidiasis caused by *C. albicans*, as demonstrated by the isolation of this species from blood, a strong ASCA response can be observed [64] which resolves after curative treatment, in contrast to the ASCA stability in CD [65]. Conversely, probing of the pathogenic phase of *C. albicans* in tissue sections from biopsies of patients with systemic *C. albicans* infection with ASCA immunopurified from CD patients showed strong reactivity [62]. Thus, there is no doubt that *C. albicans* can be the origin of ASCA [66,67] even though this does not preclude the existence of other microbial immunogens or auto-antigens (see below).

4.2. Possible mechanisms of ASCA generation by C. albicans

4.2.1. On the Candida side

4.2.1.1. S. cerevisiae and C. albicans mannans as structural models (Fig. 1). Understanding the mannosylation process, and thus the building and alteration of sequences of mannose residues acting as epitopes -and as pathogen-associated molecular patterns (PAMPS)- by *C. albicans* requires us to refer to the large number of basic structural glycobiology studies conducted over several decades complemented by the identification of genes responsible for the synthesis of mannosyl transferases (Mnts). These enzymes, located in the Golgi apparatus, establish specific linkages (either α-1,6, α-1,2, or α-1,3) with strong specificities for the acceptor molecule (the pre-existing mannoside sequence). This leads to a highly complex polymer which is more or less species specific, the archetype of which is called mannan (or more exactly, phosphopetidomannan (PPM)).

PPM is a water-soluble polysaccharide of high molecular weight bound non-covalently to the cell wall surface of yeasts. The activity of Mnts was first characterized in the PPM of *S. cerevisiae*, a yeast cell model providing many clues to our understanding of glycosylation in eukaryotic cells and the first fungal organism to be sequenced. As shown in Fig. 2, the mannose residues are branched on a protein chain, either by N-glycosidic linkages on an asparagine [68], or by O-glycosidic linkages on a serine or threonine amino acid [69]. Due to the need for large quantities of material to define the structure of the numerous mannoglycoconjugates synthesized by *C. albicans* by nuclear magnetic resonance (NMR) of native molecules or sequences released after sequential chemical or enzymic depolymerization, most studies on the variability of mannosylation have concerned PPM. Fig. 2 was derived from comprehensive reviews compiling dozens of structural papers on PPM taking in account strains and environmental variations still representing hallmarks in the domain [70,71].

4.2.1.2. Necessary extension of the model from mannan to mannoproteins (Fig. 3). Restriction of structural analysis to PPM to analyze the activity of Mnts left a completely unexplored field of research which concerned the variability of glycosylation of the wide variety of cytoplasmic and cell wall mannoproteins synthesized by *C. albicans*. Fig. 3 shows representative examples of the recognition of *C. albicans* mannoproteins in an attempt to answer this question with detailed explanations gathered from previous publications.

Despite the unquestionable issue of the relevance of anti-protein antibodies in terms of the diagnosis of host invasion by *C. albicans*, the question of their mannosylation has never been addressed, mostly because recombinant proteins generally produced in *Escherichia coli* and thus, not glycosylated, are used for diagnostic purposes. Among these are proteins that have been identified over time as *C. albicans* virulence factors (i.e., the Als family, Hwp1…). The fact that a given variable mannan epitope may be shared by these proteins depending on the growth conditions, including during the pathogenic phase, deserves our attention. The legend to Fig. 3 provides an illustration of this statement. Thus, mannosylation affects both the function of the molecule and its recognition by the immune system, and this revealed the existence of important gaps in our knowledge. In other words, and as an example, it is highly likely that the function and immune reactivity of Als3 [72,73] will depend on the environmental signals perceived by *C. albicans* cells, including under pathogenic conditions. It is anticipated that variations in Mnt activities in relation to the growth conditions (pH, temperature, osmolarity…) inhibit some β-mannosyltransferases and thus unmask α-1,2/α-1,3 linked Mans [74–76] affecting the total machinery of mannoprotein mannosylation. This has never been considered or investigated. A recent paper demonstrated that a significant part of the mannosylation regulatory process was dependent on a complex of mitochondrial proteins whose resultant form could dramatically alter the host response. [77]. Thus, we can say in conclusion that: (i) the majority of *C. albicans* proteins are mannosylated; (ii) the same epitope



Fig. 2. Schematic representation of *S. cerevisiae* (A) and *C. albicans* (B) mannans.
Mannose residues are represented by different colors according to linkage type and anomery. The arrows indicate the main reported Golgi mannosyltransferases (Mnts) involved in polymerization. The specificities and basic information regarding these Mnts are shown in the *Candida* genome database (http://www.candidagenome.org/). The specificity of the Mnts depends on the length of the oligomannose sequence, the type of linkage, and the anomery of the mannose at the non-reducing end.



Fig. 3. Western blots of *C. albicans* whole cell extracts illustrating the question of mannosyl epitope expression on various mannoproteins and their variability depending on the growth conditions. (Figures collated from previous publications, with permissions.)

Nature of the staining. Panel A: 1 - protein staining, 2 Con A staining, 3 - mAb anti-α-Man staining (mAB EBCA1), 4 - patients' sera staining. Panel B: 1 - Staining with immunopurified ASCA, 2,3 - staining with an anti-β-Man mAb (mAb 5B2) and GNL (*Galanthus nivalis* lectin*) at neutral pH., 2′,3′ - probed with an anti-β-Man mAb and GNL at acidic pH. * GNL binds to terminal α-1,3 Mans like ASCA does.

Description of the profiles. A1. Protein staining of polyacrylamide gels of whole *C. albicans* cell extracts revealed numerous well-defined bands corresponding to proteins. A2. When these molecules are transferred onto nitrocellulose for Western blotting and probed with Con A reacting with α-mannosides, larger bands appear that correspond to the mannan moieties coupled to proteins. The width of these bands increases as a function of molecular weight leading to polydispersed material (smears) accounting for heterogeneity of the mannose moiety. A3 Mapping of an α-linked oligmannose epitope recognized by a single monoclonal antibody (EBCA1) clearly shows that a single epitope may be shared by many different mannoproteins. A4. Probing of the same blot with sera from patients infected with *C. albicans* shows that a large number of mannoproteins are targets of the human antibody response.

B1 Lane 1. Probing with ASCA generated by rabbit immunization and subsequently immunopurified on *S. cerevisiae* mannan shows that the ASCA epitope is shared by many *C. albicans* mannoproteins. B. Lanes 2–3' Probing of extracts from *C. albicans* grown at neutral and acidic pH clearly shows a reduction in β-Man expression (2 to 3) by lowering the pH and a concomitant increase in the GNL signal (2′ to 3′). This demonstrate that the balance between α and β mannose expression occurring at the mannan level depending on the growth conditions (comments of Fig. 2) also concerns the mannose moiety of mannoproteins.

can be shared by several mannoproteins; (iii) the expression of the epitope can be regulated according to the growth conditions of *C. albicans*; and (iv) the ASCA epitope can be unmasked according to an expression balanced with β-mannosides [78].

Regarding the similarities between *S. cerevisiae* and *C. albicans* mannans, and the ability of the latter species to express ASCA epitopes, it is interesting to refer to the pioneering work of McKenzie et al., who showed that pre-adsorption with *C. albicans* serotype B strains removed anti-*S. cerevisiae* antibodies from CD patients' sera in contrast to serotype A strains [4]. It is worth noting that serotype A specificity is conferred by the expression of β-Mans at the non-reducing end of α-Man acid-stable linked chains [71].

Thus, it seems that combining observations from antibody analysis, structural chemistry of mannans and mannosides, and yeast mannose biosynthetic pathways reinforces our understanding of why *C. albicans* could be at the origin of ASCA [65]. The considerable bulk of knowledge gathered on *Candida* and the mycobiota obtained over the last decade led to consider this hypothesis seriously [79].

To conclude this section about possible *C. albicans* involvement in CD, a striking “coincidence” is noticed when cross-referencing research on *C. albicans* and CD. One resides in the unexpected observation by Marr et al., who reported >20 years ago that prevention of systemic *C. albicans* infection with an antifungal (fluconazole) during an immunosuppressive regimen for hematopoietic stem cell transplantation resulted in a unexpected decrease in graft-versus-host disease (GvHD) [80]. Of note, hematopoietic stem cell transplantation is a condition where patients may develop de novo IBD or an IBD flare [81]. As these patients are at high risk for invasive candidiasis, fluconazole, an antifungal developed to prevent *C. albicans* growth, might also have a preventive effect on this secondary cause of CD because of its activity on *C. albicans* [82].

4.2.2. On the host side

As far as *C. albicans* is concerned, what are the mechanisms of host (human) innate and adaptive immunity?

The question of the unique relationships between *C. albicans* and inflammation was addressed in a review, but no mention was made about which antigen(s) could be relevant or determinant in this process [9]. The discovery of CARD-9 in the genome of patients with the rare condition of chronic mucocutaneous candidiasis (CMC) [83–85] represented a hallmark in the analysis of genetic susceptibility to *C. albicans*. More recently, a single study reported the influence of the same mutation, CARD-9, together with the determinant role of CX3-CR1 on the antibody response in CD, including ASCA generation [86,87]. However, although these papers are important from the host side, they did not take into account the antigenic complexity of *C. albicans* as an indissociable partner. All molecules from the complex and variable antigenic mosaic of *C. albicans* are not equally important, as demonstrated by the strong antibody response reported in patients with CMC using older less sensitive methods such as gel precipitation, revealing multiple precipitin lines. Thus, much remains to be discovered at the molecular level about the complex mechanisms of regulation in *C. albicans* and the host response. In other words, it is difficult to anticipate that the myriad of variable Candida epitopes could be equally affected by the host regulatory response. Considerable progress has recently been made in our understanding of how *C. albicans* is sensed by innate immunity receptors

and how this sensing directs the nature of the immune response upstream towards an inflammatory or anti-inflammatory process. Sophisticated mechanisms involving host membrane, cellular, or soluble receptors were identified to respond to all major *C. albicans* cell wall components (i.e., mannans, glucans and chitin). These mechanisms and their consequences have been summarized in several comprehensive reviews [88–91]. While some therapeutic clues would hopefully be derived from this research, current investigations on adaptive immunity shows that the mechanisms involving host receptors to sense the external and symbiotic microbial communities are probably not sufficiently elaborated to lead to protection against *C. albicans*, which finds its infective niche during host immunosuppression. Thus, research on Candida faces the challenge of identifying determinant targets for adaptive immunity in a complex variable interplay, which depends on both the host's genetic background [92] and yeast commensal/infecting species/strains [93].

5. Why an ASCA auto-antigen should be considered

An important characteristic of ASCA in CD is their stability over time. Once ASCA levels have increased, sometimes long before disease onset [44,45], they remain remarkably stable during the lifetime of a patient, independently of acute or remission phase of CD [94] and medical or surgical treatments [30]. Considering a microbial hypothesis alone for ASCA generation (*C. albicans* or any other potential immunogenic microbe) does not fit with fluctuations in the microbiota classically observed in long-term studies. Regarding the half-life of immunoglobulins, a decrease in a given microbial immunogen would result in a decrease in ASCA. In a recent unpowered but informative study about the effect of antifungal treatment on the evolution of biological parameters of *C. albicans* pathogenic development and CD activity, a decrease in these latter parameters was observed over a 6-month period. In contrast, despite a decrease in *C. albicans* colonization, ASCA remained stable [82].

Thus, it would make sense to consider that once the antibody response has been triggered by exogenous microbial antigens analogous self-antigen motifs, against which a response is normally down-regulated, escape this control and maintain the stability of the ASCA response. The repertoire of oligomannose motifs express on human glycoproteins or glycolipids is extremely vast and the possibility that the ASCA epitope is expressed is not unrealistic. Furthermore, the Mnt responsible for the transfer of α-1,3 mannose, reported as preponderant in the ASCA epitope, also exists in humans. To date, several human molecules likely to support the ASCA response may be suggested from a literature analysis.

5.1. Why should glycoprotein-2 (GP2) be an ASCA auto-antigen?

The first human antigen against which an antibody response was reported to present a correlation with ASCA during CD is GP2 (zymogen granule membrane) [95]. Antibodies against both GP2 and *S. cerevisiae* mannan are associated with disease severity [96,97]. However, a dissociation between ASCA and anti-GP2 antibody responses was observed in Behcet's disease compared to CD [98]. Kurashima et al. [99] showed that GP2 was a line of defense against adhesive and invasive commensal bacteria during intestinal inflammation. GP2 expressed in Brunner glands was recently described as a putative auto-immune target in CD and celiac disease (CeD) [100]. The presence of ASCA in CeD will be discussed later.

5.2. Why should CEACAM-6 be an ASCA auto-antigen?

Among the microbes that have been identified as involved in CD pathophysiology is an *E. coli* pathotype designated adherent-invasive *E. coli* (AIEC), expressing a mannose binding adhesin [101,102] at the tip of its pili. Oligomannose glycans exposed on early apoptotic cells were identified as the preferred binding targets of AIEC, and apoptotic cells were identified as potential entry points for bacteria into the epithelial cell layer, after which the bacteria propagate laterally into the epithelial intercellular spaces [103]. The AIEC pili bind to terminal mannose of host glycoproteins, including carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6 or CD66c) [102], GP2 (see above) [104], Lamp-2 [105], and TLR4 [106]. Each of these processes is deleterious to the host by promoting bacterial invasion via M cells, or the induction of proinflammatory cytokines TNFα and IFNγ. The *CEACAM6* gene is overexpressed in most carcinomas, including those of the gastrointestinal, respiratory, and genitourinary tracts [107]. Increased serum levels of CEACAM6 serve as prognostic indicators of chronic inflammation in CD patients, given that no CEACAM6 production and mannosylation are observed in the healthy ileal mucosa [108]. In >35% of CD patients with ileal involvement, the abundance of mannosidic structures at the ileal mucosa is elevated due to overexpression of *ceacam6* by ileal epithelial cells, which favors AIEC colonization. Oligomannosylation was demonstrated at two distinct sites of CEACAM6 [103]. Strategies to saturate the carbohydrate recognition domain of FimH were developed in an attempt to prevent AIEC adhesion. A recent paper reported that TAK-018, a specific FimH blocker, successfully inhibited bacterial adhesion, preserved mucosal integrity, and prevented inflammation [109]. Some experiments involved *S. cerevisiae* strains or cell walls [110,111], these were also efficient for FimH adhesion blockade in experimental models [112]. As for the molecular receptors for FimH, CEACAM6 and GP2 receptors may be mimicked functionally by *S. cerevisiae* and its mannan and we can question whether the host molecules CEACAM6 and GP2 are able to support the ASCA response.

Direct binding of *C. albicans* to CEACAM6 has also be demonstrated [113]. A further study from the same group recently demonstrated that ligation of CEACAM6 prevented *C. albicans* binding to human neutrophils and induced an altered response of these cells [114]. In these studies, where binding was prevented by anti-CEACAM6 antibodies, it is reasonable to speculate that anti-*C. albicans* antibodies, including ASCA directed against the invasive form *in vivo,* could also prevent ligation.

5.3. The paucimannose track

Regarding the existence of α-1,3 linkages in human molecules and human immunological cross-reactivity with *S. cerevisiae*, it is interesting to note that the human gene encoding the enzyme responsible for α-1,3 Man transfer was discovered after research on *S. cerevisiae*. The *S. cerevisiae* sexual cycle with haploid mating phases has been an important model for conventional genetics by screening for mutants. This particularly concerned the early stages of protein N-glycosylation in the Golgi apparatus, which has been shown to be conserved from fungi to mammals. Glycans with short mannosidic chains corresponding to early stages of human glycoprotein synthesis are expressed in the cellular cytoplasmic compartments (endoplasmic reticulum and Golgi) before being processed in the latter compartment by mannosidases and a wide range of glycosyltransferases, leading to the highly complex repertoire of glycans found in human cells and tissues [115]. In contrast, paucimannosidic glycans, restricted to the core structure of N-glycans, are rare but may be upregulated in pathogenic conditions. It was elegantly documented that during pathogen-based activation polymorphonuclear neutrophils (PMNs) produced bioactive paucimannose-carrying proteins in their azurophilic granules [116]. The atypical glycosylation of one of these proteins, myeloperoxidase (MPO) isolated from human blood neutrophils, was fully characterized in a crystal structure [117]. It has been suggested that paucimannosylation might contribute to its presentation as a self-antigen by antigen-presenting cells and neutrophil-mediated immunity [118]. Interestingly, regarding the ASCA epitope, basic and clinical studies on paucimannose detection in humans have involved a unique monoclonal antibody, designed as mannitou IgM; binding of this monoclonal antibody was

shown to require a non-substituted α-1,3-linked mannose branch [119], a configuration defined as of high importance for ASCA binding. Considering these data together suggest that PMNs, known to be important cells for auto-antibody detection in UC with ANCA (Proteinase 3 P-R3- and MPO), could also contain some hidden auto-antigens relevant for CD. Much remains to be revealed regarding the complexity of the variation in human glycosylation patterns during health and disease [120,121]. The IgG Fc glycosylation pattern associated with the shift from pre- to inflammatory immune conditions [122] is probably worthwhile exploring for ASCA. Ultimately, tissue destruction by inflammation massively exposes normally non-accessible early stages of human glycosylation to an immune response, as well to cancer [123,124] (see below).

6. Other microbial candidates as ASCA immunogens

6.1. Yeasts

6.1.1. Saccharomyces cerevisiae complex

It is logical to start this section with the organism that remains the best producer of antigens to diagnose CD (i.e., *S. cerevisiae*). These antigens have been involved in millions of diagnostic tests over the past 30 years, made by many manufacturers across the world. Our group was at the origin of the acronym ASCA (anti-*S. cerevisiae* antibodies) created for the original ELISA test since it nicely complemented the differential diagnosis of IBD with a similar test ANCA [3]. In retrospect, this was not a good idea since it shed suspicion on a largely innocuous yeast used by humans for millennia to produce bread, wine, and beer. This unfortunate denomination for a good diagnostic test (the ASCA-ANCA paper has been cited 400 times) led to several reductionist studies aimed at proving that *S. cerevisiae* was a dreadful pathogen, without considering experience from medical mycologists. In daily practice, *S. cerevisiae* was very rarely isolated from stools and mouth swabs from the thousands of hospital patients examined each year in a university hospital, including IBD patients (records from the Mycology Department of Lille University Hospital, France). Such observations led several generations of medical mycologists to consider that *S. cerevisiae* was not adapted to thrive in the human gut, or to be an endogenous threat to human health. In contrast to conventional microbiological methods of isolation and identification, the refinement of next generation sequencing (NGS) methods over the years unambiguously confirmed that the mycobiota of IBD patients was characterized by a decreasing presence of *S. cerevisiae* DNA on the one hand and a preponderance of *C. albicans* DNA on the other [125–128].

With regard to *S. cerevisiae*, as discussed in the chapter on antigenic variability, this Linnean binominal denomination corresponds to an extremely vast repertoire of strains with specific biological [129] properties selected for food production including organoleptic properties (i.e., those selected over centuries to produce great vintage wines). Numerous species are now considered to be co-specific, such as *Saccharomyces uvarum* used for beer production and the first reported ASCA antigen [2]. However, it is indisputable that in CD patients with a triggered ASCA response, dietary *S. cerevisiae* strains will interfere with this immune response depending on their oligomannoside repertoire. This huge variablity is probably to consider since *S. cerevisiae* co-specific species *Saccharomyces boulardii*, may display both anti- *C.albicans* and anti-inflammatory properties [130,131] and a *S. cerevisiae* strain designated CNCM I-3856 prevents AIEC induced colitis in a transgenic mouse model mimicking CD [110].

6.1.2. Candida species

In addition to *C. albicans*, which has a role in ASCA generation and CD, as discussed previously, the involvement of other species of the genus *Candida* has also been investigated. Unsurprisingly, this has concerned the species most commonly isolated in clinical mycology laboratories after *C. albicans* (i.e., *Candida tropicalis* and *Candida glabrata*). These three species share a pathogenic potential that allows them to invade the mucosae, resulting in *Candida* vulvovaginitis and 90% of systemic *Candida* infections spreading from the gut.

The involvement of *C. tropicalis* (which has a mannan oligomannosidic repertoire similar to that of *C. albicans*) was suggested from the initial studies on the mycobiota associated with CD [132], as well as its correlation with ASCA levels. With the evolution of NGS methods, further studies failed to demonstrate such a preponderance of *C. tropicalis*, contradicting the results obtained by conventional mycological methods on the same patients [133]. Similarly, a study published 1 year later claimed as "the first demonstration of the existence of an altered fungal microbiota in CD patients" did not isolate *C. albicans*, but showed a preponderance of *C. glabrata* [134]. No relationship was established with ASCA levels, which probably makes sense from an immunochemical point of view since *C. glabrata* constitutively expresses the major ASCA epitope, Man α-1,3, when grown *in vitro* and identified as antigen 34 in the yeast serological classification [71]. In contrast to *C. tropicalis*, a mainly saprophytic yeast common in fruit juices, in transit, or surviving in the gut, *C. glabrata* is a truly endosaprophytic species adapted to colonize the human gut. Experimental models have clearly demonstrated its pathogenic potential in an inflammatory setting as a player able to modify bacterial communities [135,136].

Attention has recently focused on *Candida famata*, a species rarely isolated in the clinical mycology laboratory, the anamorph (asexual stage) of the species *Debaryomyces hansenii.* An elegant experimental and clinical study demonstrated that the abundance of this species in wounds and inflamed tissues was linked to its ability to dysregulate mucosal healing [137] through a specific mechanism involving myeloid cells. Interestingly, *C. famata* is among the yeast species expressing the presumptive ASCA epitope [71].

To conclude this section on yeasts, it is clear that a survey of the extensive literature on the analysis of the microbiota in IBD shows that initial studies failed to demonstrate the importance of yeast species considered by medical mycologists to be the most pathogenic and generated doubt on their possible involvement. The progressive refinement of methods and analyses clarified these points in favor of conventional mycology conclusions. A remarkable short review published recently provided very clear explanations for this evolution and explained that extreme caution and scientific humility in sampling, at the bench, or in front of the computer is of crucial importance regarding the power of methods to draw conclusions [138].

Second, it is highly probable that due to their biological richness and the models represented, namely for mannosylation, *Saccharomyces* and *Candida* yeasts have not yet reached their full potential for research on the mechanisms of ASCA generation.

6.1.3. Malassezia species

The recent incrimination of species of this complex in CD [139,140] is representative of the discrepancies between the results of metagenomic investigations based on DNA sequencing and knowledge gained on these species by mycologists 100 years ago in human and animal samples, studied by direct microscopy and culture on various specific media [141].

The classification of yeasts belonging to the *Malassezia* complex has been clarified considerably by genetic analysis. This complex is composed of 18 species including the species previously named *Pityrosporum* [142,143]. These yeasts are commensals of the human skin, thriving in the lipophilic environment of sebaceous secretions. They were also identified as opportunistic pathogens, capable of changing morphology to be associated with different clinical skin conditions, such as dandruff, seborrheic dermatitis, atopic dermatitis (where their involvement is suspected), or *Pityriasis versicolor* where the yeast invades the tissues [144,145]. With regard to the inflammatory states of atopic dermatitis or dandruff, it is not yet known whether the proliferation of *Malassezia* is the cause or the consequence. However, antifungal treatment does lead to clinical improvement. The only possible involvements reported outside the skin sphere were sepsis observed following the

unfortunate combination of two favoring circumstances, namely deep immunosuppression of premature neonates and skin contamination of lipid infusions [146].

Reports of its presence in the digestive tract as a commensal using conventional methods are scarce or non-existent. Examination of stools samples by direct microscopy does not indicate their presence. Limited data exist on the isolation of *Malassezia* from stool cultures. This yeast cannot be isolated in culture using conventional media and requires the use of lipid-enriched media [147].

Mycobiome characterization by NGS methods has highlighted the presence of *Malassezia* spp. in the stools of CD patients [126]. *Malassezia restricta* was identified in CD patients carrying a polymorphism in the CARD9 gene, involved in antifungal defense and shown experimentally to exacerbate colitis [140]. Pediatric patients with CeD were found to exhibit a 2-fold increase in *Malassezia* spp. in their intestinal mycobiome compared to a control group [148]. Of note, the discordant results in metagenomic detection of *Malassezia* spp. relates to different ribosomal RNA regions selected for high-throughput sequencing [149]. The Human Microbiome Project cohort of healthy patients revealed an unexpectedly high prevalence of *Malassezia* spp. and the presence of *M. restricta* Operational Taxonomic Unit (OTU) in up to 88.3% of samples [150]. However, these findings have not been challenged by culturomic [151], to assess yeast viability. To achieve this goal, Blachowicz et al. [152] proposed the pre-treatment of samples with propidium monoazide, intercalating the DNA of dead cells, to restrict the viable yeast metagenome. The discrepancies between metagenomic and culturomic need to be addressed to determine whether the presence of *Malassezia* spp. reflects contamination of the digestive tract by the skin microbiota where proliferation of *Malassezia* is exacerbated by systemic inflammatory disorders [145]. One mycobiome study of oral samples highlighted the high prevalence and abundance of the *Malassezia* genus among the salivary microbiota [153], in contrast to the low prevalence of *Malassezia* species in stool samples.

Regarding the immunogenicity of *Malassezia* mannan, cross-reactivity with *C. albicans* mannan has been clearly demonstrated regarding IgE, the isotype predominant in patients with atopic dermatitis [154]. Specifically, *S. cerevisiae* gp 200, to which patients with CD exhibit high reactivity [55], supports cross-antibody reactivity during atopic dermatitis [155], an inflammatory disorder in which *Malassezia* is suspected to play a role.

6.2. Mycobacteria

Among the thousands of bacterial species present in humans, many of which have been explored for their relationship with CD, the only species that has so far shown cross-reactivity with ASCA is *Mycobacterium avium subspecies paratuberculosis* [156] the etiologic agent of a severe gastroenteritis in ruminants known as Johne's disease. Two epitopes incriminate *Mycobacteria* as elicitors of antibodies in humans with CD, a terminal α-1.3 mannose [157] and a peptide sequence [158]. At the genetic level, an impressive study has demonstrated considerable overlap between susceptibility loci for IBD and mycobacterial infection [159].

6.3. Viruses

The gut virome consists of eukaryotic viruses, bacteriophages, archeal viruses, and plant viruses originating from food and environmental exposure. With roughly 108–1010 virus-like particles per gram of intestinal content, viruses make up a hefty sum of the gut microbiome [160,161]. Bacteriophages have been described as modifying the bacterial environment in a way that supports IBD development [162], whereas some strategies have been proposed to use them to target bacteria identified as playing a detrimental role [163].

Eukaryotic virome dysbiosis has been associated with IBD pathogenesis, because eukaryotic-targeting viruses integrated into the human genome may play a role in shaping mucosal immunity [161,164]. Regarding glycosylation, which is a central question in our understanding of ASCA, eukaryotic viruses take advantage of the host cells' endoplasmic reticulum and Golgi apparatus to produce complex glycans such as high-mannose and complex elongated N-glycan structures. From an evolutionary point of view, the capacity of viruses to replicate and modify their own N-glycosylation sites brings advantages for host colonization through glycan-mediated molecular mimicry. This glycan-dependent viral adaptation masks viral proteins from host neutralizing antibodies; human immunodeficiency virus, influenza virus, and severe acute respiratory syndrome related Coronavirus 2SARS-CoV-2 are major examples of this process. Some viral proteins have been implicated in the host immune response, triggering the production of anti-glycan antibodies, soluble lectins, and complement activation [165]. Among the viruses suspected to play a role in IBD pathogenesis, the Epstein-Barr virus (EBV) has been proposed as a trigger for IBD [166,167]. EBV can be considered in this setting for three main reasons: (i) host glycoproteins: EBV has a lipid envelope derived from the membranes of infected cells and bristling with host glycoprotein spicules [168]; (ii) a link with MBL deficiency: in a pediatric cohort study, analysis of mannose-binding lectin (MBL-2) genotypes and EBV antibody levels showed that EBV seropositivity was significantly lower and time to seroconversion increased in MBL-insufficient compared to MBL-sufficient children, indicating that MBL may be involved in primary EBV infection in infancy [169]. Of note, low MBL levels are also associated with pediatric IBD and ileal involvement in CD [170], as well as a high ASCA response [66,171]; (iii) persistence of antibodies: EBV infects germinal center (GC) B-cells and establishes persistent infection in memory B-cells. EBV-encoded latent membrane protein 2 A mimics B-cell antigen receptor signaling in murine GC B-cells and has also been shown to cause an altered humoral immune response and autoimmune diseases by inducing a reduction of the stringency of GC B-cell selection. It may also contribute to persistent EBV infection and pathogenesis by providing GC B-cells with excessive pro-survival effects [172].

7. ASCA and other diseases

Reaching the goal of understanding the mechanism of ASCA generation cannot be achieved without considering the panel of human diseases in which their presence has been reported. The availability of the non-invasive ASCA test incited many researchers to explore the presence of ASCA in the diseases they studied and for which they had available many sera from different patient cohorts. Over many years, the incidental observation of the presence of ASCA was confirmed by large studies. Table 1 lists the human diseases in which an increased prevalence of ASCA has been reported. This is an impressive and diverse list and it is not objective of this review to embrace the topic. Deciphering the pathophysiological mechanisms involved to explain the presence of ASCA is the domain of specialists in each of the relevant disciplines. However, when data were found and in coherence with the theme of this review, we attempted to report the changes in the gut bacteriome/mycobiome which are described in these other diseases. Instead of considering the whole and probably still incomplete panel of diseases, we first focused on diseases of the digestive tract and its appendages since some of these are important models to address some basic issues.

(i) Regarding the question of ASCA stability, a character of ASCA associated with CD discussed previously, it must be mentioned that this stability has not been documented/investigated for any other disease. Interestingly, concerning CeD, for which a triggering role for *C. albicans* has been suspected through molecular mimicry between the hyphal protein Hwp1 and gliadin (both substrates of transglutaminase) [173,174], it has been established that ASCA are not stable. Indeed, ASCA decrease under a gluten-free diet [175]. This suggests that CD and CeD differ in the genetic mechanisms leading to ASCA stability.

(ii) Regarding the question of ASCA and *C. albicans* overgrowth, studies on patients with alcoholic hepatitis probably provide the most

Table 1

Left panel. Non-exhaustive list of human diseases in which an increased prevalence of ASCA has been reported to date. The huge amount of available information led us to select a limited number of studies in an attempt at clarity. The methods of ASCA determination, usually commercially available, vary from one study to another [59,60]. The results are expressed as a % of positive tests regarding the cut-off proposed by the manufacturer for differentiating CD from UC, which is not particularly appropriate. We did not discriminate between IgG and IgA, and have reported a global range. For studies in which only statistical comparisons of groups were performed, we reported the results as an “increase”. *Right panel.* Results from gut mycobiota analyses in the corresponding diseases reporting fungal dysbiosis or *Candida* overgrowth established using metabarcoding (NGS) and/or conventional methods of mycological isolation/identification (M).

	Presence of anti-*S. cerevisiae* antibodies (ASCA)					Mycobiota		References	
	Prevalence (% or increased)	Familial trait (%)	Stability	Predictive	Diagnostic usefulness Comments	Fungal dysbiosis	*C. albicans* overgrowth	ASCA	Mycobiota
Control population	6	YES	Unknown			Low fungal diversity compared to bacterial diversity		[2,3,15]	[150]
Gut diseases									
IBDs (Inflammatory Bowel Diseases)					In association with ANCA				
Crohn's disease	50–60	20–30	YES	YES		YES	YES (NGS & culture)	[2,3]	[126,133]
Small Bowel	50–60							[192]	
Large bowel	8							[49]	
Healthy First Degree Relatives	20–30		Unknown	?			YES (culture)	[16,133]	[133]
Ulcerative colitis	11.9		Unknown			YES	YES (NGS)	[3]	[126,178]
Pouchitis	5–12.5		Increase?		Evolution close to CD	YES	YES (NGS), in patients with starch consumption	[177,193]	[181]
Celiac Disease	60–70		NO			Rather No	*Candida* genus (PCR)	[194]	[195–197]
Celiac Disease under gluten diet	8-Jun		?		Resistance to GFD?			[175]	
Candidiasis									
Systemic	72.2		NO	YES	YES	YES	YES (NGS)	[64]	[198]
Vaginal	29		NO	YES	YES	YES	YES (culture)	[199]	[200]
Hepato-biliary diseases									
NAFLD (Non Alcoholic Fatty Liver Disease)	ND					YES	YES (NGS & culture)		[201]
Primary sclerosing cholangitis	6-30					YES	Discordant studies (NGS & culture)	[202]	[203,204]
Alcoholic hepatitis	Up to 24.3		High levels pejorative		YES (linked to prognosis)	YES	YES (NGS)	[205]	[176,206]
Skin diseases									
Atopic dermatitis	ND				*S. cerevisiae* GP 200	YES	Discordant studies (NGS & culture)	[154,155]	[207]
Hidradenitis suppurativa, with chronic inflammatory intestinal disorders	Increased					Unknown	Unknown	[208,209]	[210]
Pulmonary diseases									
Cystic fibrosis	3.7–55.6		Increase in prevalence over time			YES	YES (NGS & culture) prevalence 35–93%	[211–213]	[213–215]
Autoimmune diseases									
Multiple sclerosis	3.5–15					Maybe	Discordant studies (NGS)	[216,217,219,217]	[218,219]
Behçet disease (vasculitis)	4–48.1					Unknown	Unknown	[220–222]	
Intestinal Behçet disease	12.7–25.4							[98,223,224]	

(continued on next page)

Table 1 (*continued*)

	Presence of anti-*S. cerevisiae* antibodies (ASCA)			Mycobiota		References	
Kawazaki disease (vasculitis)	Increased		Increased anti-*Candida* cell wall beta-glucan antibodies	Unknown	Unknown	[225]	
Systemic Lupus Erythematosus	4.5–31.9			YES	(*C. glabrata* culture)	[226,227]	[228]
Thyroiditis	0.8–16.6			Unknown	Unknown	[229,230]	
Sjögren Syndrome	4.8			Unknown	YES oral candidiasis (culture)	[231]	[232]
Spondyloarthritis	18–25	Unknown		YES	YES (NGS)	[233,234]	[235]
Metabolic diseases							
Diabetes	6.2–21			YES	YES (NGS & culture)	[236,237]	[201,238]
Obesity	2.1–22			YES	YES (NGS & culture)	[239,240]	[201]
Myocardial infarction	Increased			Unknown	Unknown	[241]	
Neurologic diseases							
Parkinson disease	Increased			YES	Unknown	[242]	[242,243]
Psychiatric diseases							
Autism	ND		Anti-*C. albicans* IgG antibodies in 36.5% of patients	YES	Discordant studies (cultures & NGS)	[244]	[245–247]
Depression	Increased			YES	Unknown	[248]	[249]
Schizophrenia	6–44.4			YES	Unclear (IgG anti-*C. albicans*)	[248,250–252]	[253,254]
Bipolarity	Increased			Unknown	Unknown	[255]	
Infectious diseases							
Covid-19	13.7–25			YES	YES	[256,257]	[258]
Cancer	ND		Glycosylation modification of epithelial and immune cells*	YES	Unknown	*[123,124,259] [260]	[188,261]

clear-cut model. This acute-on-chronic liver disease occurs suddenly after years of heavy alcohol consumption, for unknown reasons, and is characterized by prominent cholestasis and high mortality rates (20–40% within 6 months). Stunning of the immune system is associated with an increase in ASCA, which are associated with *Candida* overgrowth, a process clearly independent of increased intestinal permeability. Kaplan Meier curves show that ASCA levels are not only predictive, as in other diseases, but also strikingly associated with death [176]. The relation between ASCA/*Candida* overgrowth and this acute auto-immune process probably deserves attention from the scientific and medical communities.

(iii) The mystery of ASCA and UC. Although the term ASCA was proposed initially for a test differentiating the serological response in CD versus UC (with a specificity close to 100% using the ASCA-ANCA combination), an exception exists concerning pouchitis, a complication from ileo-anal anastomosis surgery. The presence of ASCA, but also anti-glycan antibodies, has led some gastroenterologists to consider this complication of UC as CD-like [177]. The relationship between ASCA and *Candida*, and the absence of ASCA in UC, raises some questions. ASCA prevalence is low in colonic forms of CD, whereas ASCA and ANCA co-exist in UC-like CD [21]; the absence of both markers corresponds to a clinico-serological entity representing >40% of cases of indeterminate colitis. The question of the relationships between *C. albicans* and ASCA extends to recent studies demonstrating that clinical improvement of UC after fecal microbiota transplant is associated with a decrease in *C. albicans* load [178,179] or improvement of clinical, histologic scores and calprotectin levels in UC patients colonized by *C. albicans* and receiving oral fluconazole therapy [180]. This suggests that the UC-based micro-mycobiota from the colon to the ileon (associated with low ASCA levels - including in CD) affects ASCA production, and that the site of *C. albicans* growth in IBD matters for ASCA generation [181].

Returning to Table 1, it is clear that during initial studies on ASCA as a marker of CD it was difficult to comprehend why so many diseases could have an increased prevalence of this marker. It should be pointed out that these prevalences are relative and that different studies used commercial tests of different origins. However, although ASCA levels often fell below those considered to be specific to CD their increase in prevalence is obvious. The fact that neurological diseases are part of this panel has been recognized over the past few decades and studies have found that the gut-brain axis as an unexpected player in human health and well-being [182]. The presence of ASCA (a response to microbial antigens) suggests that rather than an axis a triangle may exist involving the immune system, as suggested recently in premature neonates [183]. Metagenomics, allowing easy analysis of the microbiota (and technical progress in assessing the importance of the mycobiota), showed that for most of these diseases with an auto-immune background the presence of ASCA was associated with fungal dysbiosis and *Candida* overgrowth [174,184]. It is only recently that investigations into ASCA and/or *C. albicans* have extended to cancer and the literature in this field has grown. A general review from 2020 about *Candida* immunoreactivity and human diseases in different parts of the body, making reference to ASCA, proposed a framework for the human anti-fungal deterioration of colitis to cancer, but without linking ASCA to the process [10]. Overall,

two major articles addressing the topic of cancer and the mycobiota were published in Cell in 2022. One [185] identified a 20-fungus signature potentially able to distinguish pan-cancer from healthy individuals [185]. The study by Dohlman et al. [186] revealed that *Candida* is correlated with worse survival outcomes, pro-inflammatory gene expression, and metastasis, and that identification of fungal DNA at the tumor site may provide a predictive biomarker for gastrointestinal cancers. A study finely analyzing cross talk between *Candida* and immune cells uncovered regulation mechanisms promoting tumorogenesis [187]. Although impressive information has been obtained from these high-tech studies, the relation between *C. albicans* and ASCA, and ASCA and cancer, has not been addressed. Interestingly, no information can be found in the literature concerning a very simple but important question: "is there a different risk of CD evolution towards cancer in ASCA positive versus ASCA negative patients?"

Finally, convincing evidence has been found in some diseases, but the multiplicity of human pathologic circumstances where *C. albicans* overgrowth has been described makes interpretation of some of these findings in other diseases challenging. Thus, the question about *C. albicans* proliferation as a cause or consequence is legitimate. Inverse reasoning fits with the old medical adage of *C. albicans* as a sensor of human health [188]. The only response to this question would reside in clinical trials using antifungals (or probiotics?) to assess whether they improve the evolution of a patient's primary disease. Although this would probably improve a patient's clinical condition by decreasing the adverse effects of *Candida* proliferation, ethical, legal, and economic considerations render such trials challenging. It is therefore up to medical research to obtain more evidence of the impact of *C. albicans* on diseases in one way or another.

Just at the time this long-lasting review was completed, two important advances were made about ASCA and *C. albicans*. One established a clear link between ASCA and altered CD4+ T cell responses [189]. The second [190], demonstrated that severe infection led to reprograming of granulocytes. These provide new angles to revisit or answer the large number of questions still raised about ASCA meaning in human health.

8. Conclusion

This analytic review was prompted by a recent paper showing that ASCA are probably the most potent markers of CD [45], and that understanding the mechanisms of ASCA generation and persistence would help to decipher the pathophysiology of CD. Regarding the possible role of *C. albicans* in CD, we carried out early investigations on the mechanism of ASCA generation and revisit the contributions to this subject published over the past three decades. We have deliberately opted for a broad analysis of this subject by including papers on basic yeast immuno-glycobiology, medical mycology achievements, gastroenterology, and auto-immune diseases. Over many years, where numerous papers have been published in top ranked scientific journals exploring the question of *C. albicans* gut saprophytic/pathogenic adaptation in relation to the hosts' antibody response [72,73], we hope that some answers finally "emerge from the shadows" [79,191].

Ethics

Not applicable.

Funding

The study had no specific funding and was supported by the endowments of University of Lille, Inserm and CNRS, France.

Author contributions

All authors contributed to the study conception and design. Articles retrieval, data extraction, and the first draft of the manuscript were performed by Daniel Poulain and Boualem Sendid.

Declaration of Competing Interest

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:

Boualem Sendid reports administrative support, article publishing charges, and writing assistance had no specific funding and was supported by the endowments of University of Lille, Inserm and CNRS, France. Boualem Sendid reports a relationship with University of Lille that includes: employment, funding grants, speaking and lecture fees, and travel reimbursement. Other authorsdeclare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Data availability

No data was used for the research described in the article.

Acknowledgments

We thank the participants for joining the study, Laurent Dubuquoy for helpful discussions and Val Hopwood for her careful English editing.

References

[1] Sendid B, Lucidarme D, Fruit J, Cortot A, Colombel JF, D. Poulain D.. Antibodies to *Saccharomyces uvarum* : A specific marker of Crohn's disease?. In: 94th Annual Meeting of the American Gastroenterological Association, Boston, Massachusetts, May 15–21,1993. Gastroenterology. vol. 104; 1993. 779A.
[2] Sendid B, Colombel JF, Jacquinot PM, Faille C, Fruit J, Cortot A, et al. Specific antibody response to oligomannosidic epitopes in Crohn's disease. Clin Diagn Lab Immunol 1996;3:219–26.
[3] Quinton JF, Sendid B, Reumaux D, Duthilleul P, Cortot A, Grandbastien B, et al. Anti-*Saccharomyces cerevisiae* mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut 1998;42:788–91.
[4] McKenzie H, Parratt D, Main J, Pennington CR. Antigenic heterogeneity of strains of *Saccharomyces cerevisiae* and *Candida albicans* recognised by serum antibodies from patients with Crohn's disease. FEMS Microbiol Immunol 1992;4:219–24.
[5] Vermeire S, Peeters M, Rutgeerts P. Diagnostic approach to IBD. Hepatogastroenterology 2000;47:44–8.
[6] Yao F, Fan Y, Lv B, Ji C, Xu L. Diagnostic utility of serological biomarkers in patients with Crohn's disease: a case-control study. Medicine (Baltimore) 2018; 97:e11772.
[7] Bernstein CN, El-Gabalawy H, Sargent M, Landers C, Rawsthorne P, Elias B, et al. Assessing inflammatory bowel disease-associated antibodies in Caucasian and First Nations cohorts. Can J Gastroenterol 2011;25:269–73.
[8] Underhill DM, Pearlman E. Immune interactions with pathogenic and commensal fungi: a two-way street. Immunity 2015;43:845–58.
[9] Kumamoto CA. The fungal mycobiota: small numbers, large impacts. Cell Host Microbe 2016;19:750–1.
[10] Zhang D, Wang Y, Shen S, Hou Y, Chen Y, Wang T. The mycobiota of the human body: a spark can start a prairie fire. Gut Microbes 2020;11:655–79.
[11] Hsu C, Ghannoum M, Cominelli F, Martino LD. Mycobiome and inflammatory bowel disease: role in disease pathogenesis, current approaches and novel nutritional-based therapies. Inflamm Bowel Dis 2023;29:470–9.
[12] Poulain D. *Candida albicans*, plasticity and pathogenesis. Crit Rev Microbiol 2015; 41:208–17.
[13] Zhang Z, Li C, Zhao X, Lv C, He Q, Lei S, et al. Anti-*Saccharomyces cerevisiae* antibodies associate with phenotypes and higher risk for surgery in Crohn's disease: a meta-analysis. Dig Dis Sci 2012;57:2944–54.
[14] Xiong Y, Wang GZ, Zhou JQ, Xia BQ, Wang XY, Jiang B. Serum antibodies to microbial antigens for Crohn's disease progression: a meta-analysis. Eur J Gastroenterol Hepatol 2014;26:733–42.
[15] Poulain D, Sendid B, Fajardy I, Danze PM, Colombel JF. Mother to child transmission of anti-*Saccharomyces cerevisiae* mannan antibodies (ASCA) in non-IBD families. Gut 2000;47:870–1.
[16] Sendid B, Quinton JF, Charrier G, Goulet O, Cortot A, Grandbastien B, et al. Anti-*Saccharomyces cerevisiae* mannan antibodies in familial Crohn's disease. Am J Gastroenterol 1998;93:1306–10.
[17] Ruemmele FM, Targan SR, Levy G, Dubinsky M, Braun J, Seidman EG. Diagnostic accuracy of serological assays in pediatric inflammatory bowel disease. Gastroenterology 1998;115:822–9.
[18] Peeters M, Joossens S, Vermeire S, Vlietinck R, Bossuyt X, Rutgeerts P. Diagnostic value of anti-*Saccharomyces cerevisiae* and antineutrophil cytoplasmic

autoantibodies in inflammatory bowel disease. Am J Gastroenterol 2001;96: 730–4.
[19] Sokollik C, Pahud de Mortanges A, Leichtle AB, Juillerat P, Horn MP, Swiss IBD Cohort Study Group. Machine learning in antibody diagnostics for inflammatory bowel disease subtype classification. Diagnostics (Basel) 2023;13.
[20] Dotan I, Fishman S, Dgani Y, Schwartz M, Karban A, Lerner A, et al. Antibodies against laminaribioside and chitobioside are novel serologic markers in Crohn's disease. Gastroenterology 2006;131:366–78.
[21] Joossens S, Reinisch W, Vermeire S, Sendid B, Poulain D, Peeters M, et al. The value of serologic markers in indeterminate colitis: a prospective follow-up study. Gastroenterology 2002;122:1242–7.
[22] Mow WS, Vasiliauskas EA, Lin YC, Fleshner PR, Papadakis KA, Taylor KD, et al. Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease. Gastroenterology 2004;126:414–24.
[23] Forcione DG, Rosen MJ, Kisiel JB, Sands BE. Anti-*Saccharomyces cerevisiae* antibody (ASCA) positivity is associated with increased risk for early surgery in Crohn's disease. Gut 2004;53:1117–22.
[24] Vasiliauskas EA, Kam LY, Karp LC, Gaiennie J, Yang H, Targan SR. Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics. Gut 2000;47: 487–96.
[25] Rieder F, Schleder S, Wolf A, Dirmeier A, Strauch U, Obermeier F, et al. Serum anti-glycan antibodies predict complicated Crohn's disease behavior: a cohort study. Inflamm Bowel Dis 2010;16:1367–75.
[26] Rieder F, Schleder S, Wolf A, Dirmeier A, Strauch U, Obermeier F, et al. Association of the novel serologic anti-glycan antibodies anti-laminarin and anti-chitin with complicated Crohn's disease behavior. Inflamm Bowel Dis 2010;16: 263–74.
[27] Amre DK, Lu SE, Costea F, Seidman EG. Utility of serological markers in predicting the early occurrence of complications and surgery in pediatric Crohn's disease patients. Am J Gastroenterol 2006;101:645–52.
[28] Jiang M, Zeng Z, Chen K, Dang Y, Li L, Ma C, et al. Enterogenous microbiotic markers in the differential diagnosis of Crohn's disease and intestinal tuberculosis. Front Immunol 2022;13:820891.
[29] Kaul A, Hutfless S, Liu L, Bayless TM, Marohn MR, Li X. Serum anti-glycan antibody biomarkers for inflammatory bowel disease diagnosis and progression: a systematic review and meta-analysis. Inflamm Bowel Dis 2012;18:1872–84.
[30] Kristensen VA, Cvancarova M, Hoivik ML, Moum B, Vatn MH. Serological antibodies and surgery in a population-based inception cohort of Crohn's disease patients - the IBSEN study. Scand J Gastroenterol 2020;55:436–41.
[31] Rieder F, Fiocchi C, Rogler G. Mechanisms, management, and treatment of fibrosis in patients with inflammatory bowel diseases. Gastroenterology 2017; 152:340–350 e6.
[32] Giuffrida P, Pinzani M, Corazza GR, Di Sabatino A. Biomarkers of intestinal fibrosis - one step towards clinical trials for structuring inflammatory bowel disease. United Eur Gastroenterol J 2016;4:523–30.
[33] Ricciuto A, Aardoom M, Orlanski-Meyer E, Navon D, Carman N, Aloi M, et al. Pediatric inflammatory bowel disease-ahead steering, predicting outcomes in pediatric Crohn's disease for management optimization: systematic review and consensus statements from the pediatric inflammatory bowel disease-ahead program. Gastroenterology 2021;160:403–436 e26.
[34] Hoffenberg EJ, Fidanza S, Sauaia A. Serologic testing for inflammatory bowel disease. J Pediatr 1999;134:447–52.
[35] Mainardi E, Villanacci V, Bassotti G, Liserre B, Rossi E, Incardona P, et al. Diagnostic value of serological assays in pediatric inflammatory bowel disorders. Digestion 2007;75:210–4.
[36] Levine A, Koletzko S, Turner D, Escher JC, Cucchiara S, de Ridder L, et al. ESPGHAN revised porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents. J Pediatr Gastroenterol Nutr 2014;58:795–806.
[37] Olbjorn C, Cvancarova Smastuen M, Thiis-Evensen E, Nakstad B, Vatn MH, Perminow G. Serological markers in diagnosis of pediatric inflammatory bowel disease and as predictors for early tumor necrosis factor blocker therapy. Scand J Gastroenterol 2017;52:414–9.
[38] Chandrakumar A, Georgy M, Agarwal P, Jong GW t, El-Matary W. Anti-*Saccharomyces cerevisiae* antibodies as a prognostic biomarker in children with Crohn disease. J Pediatr Gastroenterol Nutr 2019;69:82–7.
[39] Seibold F, Stich O, Hufnagl R, Kamil S, Scheurlen M. Anti-*Saccharomyces cerevisiae* antibodies in inflammatory bowel disease: a family study. Scand J Gastroenterol 2001;36:196–201.
[40] Vermeire S, Peeters M, Vlietinck R, Joossens S, Den Hond E, Bulteel V, et al. Anti-*Saccharomyces cerevisiae* antibodies (ASCA), phenotypes of IBD, and intestinal permeability: a study in IBD families. Inflamm Bowel Dis 2001;7:8–15.
[41] Halfvarson J, Standaert-Vitse A, Jarnerot G, Sendid B, Jouault T, Bodin L, et al. Anti-*Saccharomyces cerevisiae* antibodies in twins with inflammatory bowel disease. Gut 2005;54:1237–43.
[42] Prideaux L, De Cruz P, Ng SC, Kamm MA. Serological antibodies in inflammatory bowel disease: a systematic review. Inflamm Bowel Dis 2012;18:1340–55.
[43] Landers CJ, Cohavy O, Misra R, Yang H, Lin YC, Braun J, et al. Selected loss of tolerance evidenced by Crohn's disease-associated immune responses to auto- and microbial antigens. Gastroenterology 2002;123:689–99.
[44] Israeli E, Grotto I, Gilburd B, Balicer RD, Goldin E, Wiik A, et al. Anti-*Saccharomyces cerevisiae* and antineutrophil cytoplasmic antibodies as predictors of inflammatory bowel disease. Gut 2005;54:1232–6.
[45] Torres J, Petralia F, Sato T, Wang P, Telesco SE, Choung RS, et al. Serum biomarkers identify patients who will develop inflammatory bowel diseases up to 5 years before diagnosis. Gastroenterology 2020;159:96–104.
[46] Jayasooriya N, Baillie S, Blackwell J, Bottle A, Petersen I, Creese H, et al. Systematic review with meta-analysis: time to diagnosis and the impact of delayed diagnosis on clinical outcomes in inflammatory bowel disease. Aliment Pharmacol Ther 2023;57:635–52.
[47] Young M, Davies MJ, Bailey D, Gradwell MJ, Smestad-Paulsen B, Wold JK, et al. Characterization of oligosaccharides from an antigenic mannan of *Saccharomyces cerevisiae*. Glycoconj J 1998;15:815–22.
[48] Chevalier R, Esnault J, Vandewalle P, Sendid B, Colombel JF, Poulain D, et al. Synthetic yeast oligomannosides as biological probes: α-D-man(1->3) α-D-man(1->2) α-D-man and α-D-man(1->3) α-D-man(1->2) α-D-man(1->2) α-D-man as Crohn's disease marker. Tetrahedron 2005;61:7669–77.
[49] Vandewalle-El Khoury P, Colombel JF, Joossens S, Standaert-Vitse A, Collot M, Halfvarson J, et al. Detection of antisynthetic mannoside antibodies (ASigmaMA) reveals heterogeneity in the ASCA response of Crohn's disease patients and contributes to differential diagnosis, stratification, and prediction. Am J Gastroenterol 2008;103:949–57.
[50] Despras G, Robert R, Sendid B, Machez E, Poulain D, Mallet JM. Biotin sulfone tagged oligomannosides as immunogens for eliciting antibodies against specific mannan epitopes. Bioorg Med Chem 2012;20:1817–31.
[51] McKenzie H, Main J, Pennington CR, Parratt D. Antibody to selected strains of *Saccharomyces cerevisiae* (baker's and brewer's yeast) and *Candida albicans* in Crohn's disease. Gut 1990;31:536–8.
[52] Cantelli C, Trinel PA, Bernigaud A, Jouault T, Polonelli L, Poulain D. Mapping of beta-1,2-linked oligomannosidic epitopes among glycoconjugates of *Candida* species. Microbiology (Reading) 1995;141(Pt 10):2693–7.
[53] Fradin C, Slomianny MC, Mille C, Masset A, Robert R, Sendid B, et al. Beta-1,2 oligomannose adhesin epitopes are widely distributed over the different families of *Candida albicans* cell wall mannoproteins and are associated through both N- and O-glycosylation processes. Infect Immun 2008;76:4509–17.
[54] Trinel PA, Faille C, Jacquinot PM, Cailliez JC, Poulain D. Mapping of *Candida albicans* oligomannosidic epitopes by using monoclonal antibodies. Infect Immun 1992;60:3845–51.
[55] Sander U, Kunze I, Bröker M, Kunze G. Humoral immune response to a 200-kDa glycoprotein antigen of *Saccharomyces cerevisiae* is common in man. Immunol Lett 1998;61:113–7.
[56] Broker M, Harthus HP, Barnes RM. A murine monoclonal antibody directed against a yeast cell wall glycoprotein antigen of the yeast genus *Saccharomyces*. FEMS Microbiol Lett 1994;118:297–304.
[57] Dotan I. New serologic markers for inflammatory bowel disease diagnosis. Dig Dis 2010;28:418–23.
[58] Hadrich I, Vandewalle P, Cheikhrouhou F, Makni F, Krichen MS, Sendid B, et al. Ethnic and socio-cultural specificities in Tunisia have no impact on the prevalence of anti-*Saccharomyces cerevisiae* antibodies in Crohn's disease patients, their relatives or associated clinical factors. Scand J Gastroenterol 2007;42: 717–25.
[59] Vermeire S, Joossens S, Peeters M, Monsuur F, Marien G, Bossuyt X, et al. Comparative study of ASCA (anti-*Saccharomyces cerevisiae* antibody) assays in inflammatory bowel disease. Gastroenterology 2001;120:827–33.
[60] Annese V, Piepoli A, Perri F, Lombardi G, Latiano A, Napolitano G, et al. Anti-*Saccharomyces cerevisiae* mannan antibodies in inflammatory bowel disease: comparison of different assays and correlation with clinical features. Aliment Pharmacol Ther 2004;20:1143–52.
[61] Nelson A, Stewart CJ, Kennedy NA, Lodge JK, Tremelling M, Consortium UIG, et al. The impact of NOD2 genetic variants on the gut mycobiota in Crohn's disease patients in remission and in individuals without gastrointestinal inflammation. J Crohns Colitis 2021;15:800–12.
[62] Standaert-Vitse A, Jouault T, Vandewalle P, Mille C, Seddik M, Sendid B, et al. *Candida albicans* is an immunogen for anti-*Saccharomyces cerevisiae* antibody markers of Crohn's disease. Gastroenterology 2006;130:1764–75.
[63] Jawhara S, Thuru X, Standaert-Vitse A, Jouault T, Mordon S, Sendid B, et al. Colonization of mice by *Candida albicans* is promoted by chemically induced colitis and augments inflammatory responses through galectin-3. J Infect Dis 2008;197:972–80.
[64] Sendid B, Dotan N, Nseir S, Savaux C, Vandewalle P, Standaert A, et al. Antibodies against glucan, chitin, and *Saccharomyces cerevisiae* mannan as new biomarkers of *Candida albicans* infection that complement tests based on *C. albicans* mannan. Clin Vaccine Immunol 2008;15:1868–77.
[65] Poulain D, Sendid B, Standaert-Vitse A, Fradin C, Jouault T, Jawhara S, et al. Yeasts: neglected pathogens. Dig Dis 2009;27(Suppl. 1):104–10.
[66] Muller S, Schaffer T, Flogerzi B, Seibold-Schmid B, Schnider J, Takahashi K, et al. Mannan-binding lectin deficiency results in unusual antibody production and excessive experimental colitis in response to mannose-expressing mild gut pathogens. Gut 2010;59:1493–500.
[67] Schaffer T, Muller S, Flogerzi B, Seibold-Schmid B, Schoepfer AM, Seibold F. Anti-*Saccharomyces cerevisiae* mannan antibodies (ASCA) of Crohn's patients crossreact with mannan from other yeast strains, and murine ASCA IgM can be experimentally induced with *Candida albicans*. Inflamm Bowel Dis 2007;13: 1339–46.
[68] Dean N. Asparagine-linked glycosylation in the yeast Golgi. Biochim Biophys Acta 1999;1426:309–22.
[69] Loibl M, Strahl S. Protein O-mannosylation: what we have learned from baker's yeast. Biochim Biophys Acta 1833;2013:2438–46.
[70] Nelson RD, Shibata N, Podzorski RP, Herron MJ. *Candida* mannan: chemistry, suppression of cell-mediated immunity, and possible mechanisms of action. Clin Microbiol Rev 1991;4:1–19.

[71] Shibata N, Kobayashi H, Suzuki S. Immunochemistry of pathogenic yeast, *Candida* species, focusing on mannan. Proc Jpn Acad Ser B Phys Biol Sci 2012;88: 250–65.

[72] Doron I, Mesko M, Li XV, Kusakabe T, Leonardi I, Shaw DG, et al. Mycobiota-induced IgA antibodies regulate fungal commensalism in the gut and are dysregulated in Crohn's disease. Nat Microbiol 2021;6:1493–504.

[73] Ost KS, O'Meara TR, Stephens WZ, Chiaro T, Zhou H, Penman J, et al. Adaptive immunity induces mutualism between commensal eukaryotes. Nature 2021;596: 114–8.

[74] Kobayashi H, Giummelly P, Takahashi S, Ishida M, Sato J, Takaku M, et al. *Candida albicans* serotype A strains grow in yeast extract-added Sabouraud liquid medium at pH 2.0, elaborating mannans without beta-1,2 linkage and phosphate group. Biochem Biophys Res Commun 1991;175:1003–9.

[75] Okawa Y, Takahata T, Kawamata M, Miyauchi M, Shibata N, Suzuki A, et al. Temperature-dependent change of serological specificity of *Candida albicans* NIH A-207 cells cultured in yeast extract-added Sabouraud liquid medium: disappearance of surface antigenic factors 4, 5, and 6 at high temperature. FEBS Lett 1994;345:167–71.

[76] Shibata N, Suzuki A, Kobayashi H, Okawa Y. Chemical structure of the cell-wall mannan of *Candida albicans* serotype A and its difference in yeast and hyphal forms. Biochem J 2007;404:365–72.

[77] She X, Zhang P, Shi D, Peng J, Wang Q, Meng X, et al. The mitochondrial complex I proteins of *Candida albicans* moderate phagocytosis and the production of pro-inflammatory cytokines in murine macrophages and dendritic cells. FASEB J 2022;36.

[78] Leroy J, Lecointe K, Coulon P, Sendid B, Robert R, Poulain D. Antibodies as models and tools to decipher *Candida albicans* pathogenic development: review about a unique monoclonal antibody reacting with immunomodulatory adhesins. J Fungi (Basel) 2023 May 31;9(6):636.

[79] Iliev ID. Mycobiota-host immune interactions in IBD: coming out of the shadows. Nat Rev Gastroenterol Hepatol 2022 Feb;19(2):91–2.

[80] Marr KA, Seidel K, Slavin MA, Bowden RA, Schoch HG, Flowers ME, et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood 2000;96:2055–61.

[81] Ghouri YA, Tahan V, Shen B. Secondary causes of inflammatory bowel diseases. World J Gastroenterol 2020;26:3998–4017.

[82] Sendid B, Salvetat N, Sarter H, Loridant S, Cunisse C, Francois N, et al. A pilot clinical study on post-operative recurrence provides biological clues for a role of *Candida* yeasts and fluconazole in Crohn's disease. J Fungi (Basel) 2021;7:324.

[83] Puel A, Picard C, Cypowyj S, Lilic D, Abel L, Casanova JL. Inborn errors of mucocutaneous immunity to *Candida albicans* in humans: a role for IL-17 cytokines? Curr Opin Immunol 2010;22:467–74.

[84] Glocker EO, Hennigs A, Nabavi M, Schaffer AA, Woellner C, Salzer U, et al. A homozygous CARD9 mutation in a family with susceptibility to fungal infections. N Engl J Med 2009;361:1727–35.

[85] Okada S, Puel A, Casanova JL, Kobayashi M. Chronic mucocutaneous candidiasis disease associated with inborn errors of IL-17 immunity. Clin Transl Immunology 2016;5:e114.

[86] Doron I, Leonardi I, Li X, Fiers W, Semon A, Bialt-DeCelie M, et al. Human gut mycobiota tune immunity via CARD9-dependent induction of anti-fungal IgG antibodies. Cell 2021;184.

[87] Lamas B, Richard ML, Leducq V, Pham HP, Michel ML, Da Costa G, et al. CARD9 impacts colitis by altering gut microbiota metabolism of tryptophan into aryl hydrocarbon receptor ligands. Nat Med 2016;22:598–605.

[88] Jouault T, Sarazin A, Martinez-Esparza M, Fradin C, Sendid B, Poulain D. Host responses to a versatile commensal: PAMPs and PRRs interplay leading to tolerance or infection by *Candida albicans*. Cell Microbiol 2009;11:1007–15.

[89] Brown AJ, Brown GD, Netea MG, Gow NA. Metabolism impacts upon *Candida* immunogenicity and pathogenicity at multiple levels. Trends Microbiol 2014;22: 614–22.

[90] Netea MG, Brown GD, Kullberg BJ, Gow NA. An integrated model of the recognition of *Candida albicans* by the innate immune system. Nat Rev Microbiol 2008;6:67–78.

[91] Netea MG, Joosten LA, van der Meer JW, Kullberg BJ, van de Veerdonk FL. Immune defence against *Candida* fungal infections. Nat Rev Immunol 2015;15: 630–42.

[92] Leonardi I, Li X, Semon A, Li D, Doron I, Putzel G, et al. CX3CR1(+) mononuclear phagocytes control immunity to intestinal fungi. Science 2018;359:232–6.

[93] Li X, Leonardi I, Putzel G, Semon A, Fiers W, Kusakabe T, et al. Immune regulation by fungal strain diversity in inflammatory bowel disease. Nature 2022: 1–7.

[94] Gerard R, Sendid B, Techy A, Vernier-Massouille G, Jouault T, Colombel J, et al. *Candida albicans* colonization and anti-glycan antibodies in active and quiescent Crohn's disease. J Crohns Colitis 2013;7:S290–1.

[95] Roggenbuck D, Reinhold D, Wex T, Goihl A, von Arnim U, Malfertheiner P, et al. Autoantibodies to GP2, the major zymogen granule membrane glycoprotein, are new markers in Crohn's disease. Clin Chim Acta 2011;412:718–24.

[96] Bonneau J, Dumestre-Perard C, Rinaudo-Gaujous M, Genin C, Sparrow M, Roblin X, et al. Systematic review: new serological markers (anti-glycan, anti-GP2, anti-GM-CSF Ab) in the prediction of IBD patient outcomes. Autoimmun Rev 2015;14:231–45.

[97] Papp M, Lakatos PL. Serological studies in inflammatory bowel disease: how important are they? Curr Opin Gastroenterol 2014;30:359–64.

[98] Zhang S, Luo J, Wu Z, Roggenbuck D, Schierack P, Reinhold D, et al. Antibodies against glycoprotein 2 display diagnostic advantages over ASCA in distinguishing CD from intestinal tuberculosis and intestinal Behcet's disease. Clin Transl Gastroenterol 2018;9:e133.

[99] Kurashima Y, Kigoshi T, Murasaki S, Arai F, Shimada K, Seki N, et al. Pancreatic glycoprotein 2 is a first line of defense for mucosal protection in intestinal inflammation. Nat Commun 2021;12:1067.

[100] Roggenbuck D, Goihl A, Sowa M, Lopens S, Rödiger S, Schierack P, et al. Human glycoprotein-2 expressed in Brunner glands – a putative autoimmune target and link between Crohn's and coeliac disease. Clin Immunol 2023;247:109214.

[101] Darfeuille-Michaud A, Boudeau J, Bulois P, Neut C, Glasser AL, Barnich N, et al. High prevalence of adherent-invasive *Escherichia coli* associated with ileal mucosa in Crohn's disease. Gastroenterology 2004;127:412–21.

[102] Barnich N, Darfeuille-Michaud A. Abnormal CEACAM6 expression in Crohn disease patients favors gut colonization and inflammation by adherent-invasive *E. coli*. Virulence 2010;1:281–2.

[103] Dumych T, Yamakawa N, Sivignon A, Garenaux E, Robakiewicz S, Coddeville B, et al. Oligomannose-rich membranes of dying intestinal epithelial cells promote host colonization by adherent-invasive *E. coli*. Front Microbiol 2018;9:742.

[104] Ohno H, Hase K. Glycoprotein 2 (GP2): grabbing the FimH bacteria into M cells for mucosal immunity. Gut Microbes 2010;1:407–10.

[105] Kain R, Exner M, Brandes R, Ziebermayr R, Cunningham D, Alderson CA, et al. Molecular mimicry in pauci-immune focal necrotizing glomerulonephritis. Nat Med 2008;14:1088–96.

[106] Fischer H, Yamamoto M, Akira S, Beutler B, Svanborg C. Mechanism of pathogen-specific TLR4 activation in the mucosa: fimbriae, recognition receptors and adaptor protein selection. Eur J Immunol 2006;36:267–77.

[107] Gemei M, Mirabelli P, Di Noto R, Corbo C, Iaccarino A, Zamboli A, et al. CD66c is a novel marker for colorectal cancer stem cell isolation, and its silencing halts tumor growth in vivo. Cancer 2013;119:729–38.

[108] Barnich N, Carvalho FA, Glasser AL, Darcha C, Jantscheff P, Allez M, et al. CEACAM6 acts as a receptor for adherent-invasive *E. coli*, supporting ileal mucosa colonization in Crohn disease. J Clin Invest 2007;117:1566–74.

[109] Chevalier G, Laveissiere A, Desachy G, Barnich N, Sivignon A, Maresca M, et al. Blockage of bacterial FimH prevents mucosal inflammation associated with Crohn's disease. Microbiome 2021;9:176.

[110] Sivignon A, de Vallee A, Barnich N, Denizot J, Darcha C, Pignede G, et al. *Saccharomyces cerevisiae* CNCM I-3856 prevents colitis induced by AIEC bacteria in the transgenic mouse model mimicking Crohn's disease. Inflamm Bowel Dis 2015;21:276–86.

[111] Sivignon A, Yu SY, Ballet N, Vandekerckove P, Barnich N, Guerardel Y. Heteropolysaccharides from *S. cerevisiae* show anti-adhesive properties against *E. coli* associated with Crohn's disease. Carbohydr Polym 2021;271:118415.

[112] Dumych T, Bridot C, Gouin SG, Lensink MF, Paryzhak S, Szunerits S, et al. A novel integrated way for deciphering the glycan code for the FimH lectin. Molecules 2018;23.

[113] Klaile E, Muller MM, Schafer MR, Clauder AK, Feer S, Heyl KA, et al. Binding of *Candida albicans* to human CEACAM1 and CEACAM6 modulates the inflammatory response of intestinal epithelial cells. MBio 2017;8.

[114] Klaile E, Prada Salcedo JP, Klassert TE, Besemer M, Bothe AK, Durotin A, et al. Antibody ligation of CEACAM1, CEACAM3, and CEACAM6, differentially enhance the cytokine release of human neutrophils in responses to *Candida albicans*. Cell Immunol 2021;371:104459.

[115] Lee MH, Hsu TL, Lin JJ, Lin YJ, Kao YY, Chang JJ, et al. Constructing a human complex type N-linked glycosylation pathway in *Kluyveromyces marxianus*. PloS One 2020;15:e0233492.

[116] Thaysen-Andersen M, Venkatakrishnan V, Loke I, Laurini C, Diestel S, Parker BL, et al. Human neutrophils secrete bioactive paucimannosidic proteins from azurophilic granules into pathogen-infected sputum. J Biol Chem 2015;290: 8789–802.

[117] Krawczyk L, Semwal S, Soubhye J, Lemri Ouadriri S, Prevost M, Van Antwerpen P, et al. Native glycosylation and binding of the antidepressant paroxetine in a low-resolution crystal structure of human myeloperoxidase. Acta Crystallogr D Struct Biol 2022;78:1099–109.

[118] Reiding KR, Franc V, Huitema MG, Brouwer E, Heeringa P, Heck AJR. Neutrophil myeloperoxidase harbors distinct site-specific peculiarities in its glycosylation. J Biol Chem 2019;294:20233–45.

[119] Robakiewicz S, Bridot C, Serna S, Gimeno A, Echeverria B, Delgado S, et al. Minimal epitope for Mannitou IgM on paucimannose-carrying glycoproteins. Glycobiology 2021;31:1005–17.

[120] Čaval T, Heck AJR, Reiding KR. Meta-heterogeneity: evaluating and describing the diversity in glycosylation between sites on the same glycoprotein. Mol Cell Proteomics 2021;20:100010.

[121] Robbe Masselot C, Cordier C, Marsac B, Nachury M, Leonard R, Sendid B. Human fecal mucin glycosylation as a new biomarker in inflammatory bowel diseases. Inflamm Bowel Dis 2023;29:167–71.

[122] Buhre JS, Becker M, Ehlers M. IgG subclass and Fc glycosylation shifts are linked to the transition from pre- to inflammatory autoimmune conditions. Front Immunol 2022;13:1006939.

[123] Zhang X. Alterations of golgi structural proteins and glycosylation defects in cancer. Front Cell Dev Biol 2021;9:665289.

[124] Brazil JC, Parkos CA. Finding the sweet spot: glycosylation mediated regulation of intestinal inflammation. Mucosal Immunol 2022;15:211–22.

[125] Hoarau G, Mukherjee PK, Gower-Rousseau C, Hager C, Chandra J, Retuerto MA, et al. Bacteriome and mycobiome interactions underscore microbial dysbiosis in familial Crohn's disease. mBio 2016;7. e01250-16.

[126] Sokol H, Leducq V, Aschard H, Pham HP, Jegou S, Landman C, et al. Fungal microbiota dysbiosis in IBD. Gut 2017;66:1039–48.

[127] Li XV, Leonardi I, Iliev ID. Gut mycobiota in immunity and inflammatory disease. Immunity 2019;50:1365–79.
[128] van Thiel I, de Jonge W, van den Wijngaard R. Fungal feelings in the irritable bowel syndrome: the intestinal mycobiome and abdominal pain. Gut Microbes 2023;15:2168992.
[129] MacKenzie DA, Defernez M, Dunn WB, Brown M, Fuller LJ, de Herrera SR, et al. Relatedness of medically important strains of *Saccharomyces cerevisiae* as revealed by phylogenetics and metabolomics. Yeast 2008;25:501–12.
[130] Jawhara S, Habib K, Maggiotto F, Pignede G, Vandekerckove P, Maes E, et al. Modulation of intestinal inflammation by yeasts and cell wall extracts: strain dependence and unexpected anti-inflammatory role of glucan fractions. PloS One 2012;7:e40648.
[131] Jawhara S, Poulain D. *Saccharomyces boulardii* decreases inflammation and intestinal colonization by *Candida albicans* in a mouse model of chemically-induced colitis. Med Mycol 2007;45:691–700.
[132] Mukherjee PK, Sendid B, Hoarau G, Colombel JF, Poulain D, Ghannoum MA. Mycobiota in gastrointestinal diseases. Nat Rev Gastroenterol Hepatol 2015;12:77–87.
[133] Standaert-Vitse A, Sendid B, Joossens M, Francois N, Vandewalle-El Khoury P, Branche J, et al. *Candida albicans* colonization and ASCA in familial Crohn's disease. Am J Gastroenterol 2009;104:1745–53.
[134] Liguori G, Lamas B, Richard ML, Brandi G, da Costa G, Hoffmann TW, et al. Fungal dysbiosis in mucosa-associated microbiota of Crohn's disease patients. J Crohns Colitis 2016;10:296–305.
[135] Charlet R, Bortolus C, Barbet M, Sendid B, Jawhara S. A decrease in anaerobic bacteria promotes *Candida glabrata* overgrowth while beta-glucan treatment restores the gut microbiota and attenuates colitis. Gut Pathog 2018;10:50.
[136] Charlet R, Pruvost Y, Tumba G, Istel F, Poulain D, Kuchler K, et al. Remodeling of the *Candida glabrata* cell wall in the gastrointestinal tract affects the gut microbiota and the immune response. Sci Rep 2018;8:3316.
[137] Jain U, Ver Heul AM, Xiong S, Gregory MH, Demers EG, Kern JT, et al. *Debaryomyces* is enriched in Crohn's disease intestinal tissue and impairs healing in mice. Science 2021;371:1154–9.
[138] Thielemann N, Herz M, Kurzai O, Martin R. Analyzing the human gut mycobiome – a short guide for beginners. Comput Struct Biotechnol J 2022;20:608–14.
[139] Olaisen M, Richard ML, Beisvag V, Granlund AVB, Royset ES, Rue O, et al. The ileal fungal microbiota is altered in Crohn's disease and is associated with the disease course. Front Med (Lausanne) 2022;9:868812.
[140] Limon JJ, Tang J, Li D, Wolf AJ, Michelsen KS, Funari V, et al. *Malassezia* is associated with Crohn's disease and exacerbates colitis in mouse models. Cell Host Microbe 2019;25:377–388 e6.
[141] Guillot J, Hadina S, Gueho E. The genus *Malassezia*: old facts and new concepts. Parassitologia 2008;50:77–9.
[142] Ianiri G, LeibundGut-Landmann S, Dawson Jr TL. *Malassezia*: a commensal, pathogen, and mutualist of human and animal skin. Annu Rev Microbiol 2022;76:757–82.
[143] Theelen B, Cafarchia C, Gaitanis G, Bassukas ID, Boekhout T, Dawson Jr TL. *Malassezia* ecology, pathophysiology, and treatment. Med Mycol 2018;56:S10–25.
[144] Tragiannidis A, Bisping G, Koehler G, Groll AH. Minireview: *Malassezia* infections in immunocompromised patients. Mycoses 2010;53:187–95.
[145] Abdillah A, Ranque S. Chronic diseases associated with *Malassezia* yeast. J Fungi (Basel) 2021;7:855.
[146] Rhimi W, Theelen B, Boekhout T, Otranto D, Cafarchia C. *Malassezia* spp. yeasts of emerging concern in fungemia. Front Cell Infect Microbiol 2020;10:370.
[147] Abdillah A, Ranque S. MalaSelect: a selective culture medium for *Malassezia* species. J Fungi (Basel) 2021;7:824.
[148] Krawczyk A, Salamon D, Kowalska-Duplaga K, Zapala B, Ksiazek T, Drazniuk-Warchol M, et al. Changes in the gut mycobiome in pediatric patients in relation to the clinical activity of Crohn's disease. World J Gastroenterol 2023;29:2172–87.
[149] Hoggard M, Vesty A, Wong G, Montgomery JM, Fourie C, Douglas RG, et al. Characterizing the human mycobiota: a comparison of small subunit rRNA, ITS1, ITS2, and large subunit rRNA genomic targets. Front Microbiol 2018;9:2208.
[150] Nash AK, Auchtung TA, Wong MC, Smith DP, Gesell JR, Ross MC, et al. The gut mycobiome of the human microbiome project healthy cohort. Microbiome 2017;5:153.
[151] Hamad I, Ranque S, Azhar EI, Yasir M, Jiman-Fatani AA, Tissot-Dupont H, et al. Culturomics and amplicon-based metagenomic approaches for the study of fungal population in human gut microbiota. Sci Rep 2017;7:16788.
[152] Blachowicz A, Mhatre S, Singh NK, Wood JM, Parker CW, Ly C, et al. The isolation and characterization of rare mycobiome associated with spacecraft assembly cleanrooms. Front Microbiol 2022;13:777133.
[153] Dupuy AK, David MS, Li L, Heider TN, Peterson JD, Montano EA, et al. Redefining the human oral mycobiome with improved practices in amplicon-based taxonomy: discovery of *Malassezia* as a prominent commensal. PloS One 2014;9:e90899.
[154] Savolainen J, Broberg A. Crossreacting IgE antibodies to *Pityrosporum ovale* and *Candida albicans* in atopic children. Clin Exp Allergy 1992;22:469–74.
[155] Nenoff P, Muller B, Sander U, Kunze G, Broker M, Haustein UF. IgG and IgE immune response against the surface glycoprotein gp200 of *Saccharomyces cerevisiae* in patients with atopic dermatitis. Mycopathologia 2001;152:15–21.
[156] Biet F, Gendt L, Anton E, Ballot E, Hugot JP, Johanet C. Serum antibodies to *Mycobacterium avium* subspecies paratuberculosis combined with anti-*Saccharomyces cerevisiae* antibodies in Crohn's disease patients: prevalence and diagnostic role. Dig Dis Sci 2011;56:1794–800.
[157] Mpofu CM, Campbell BJ, Subramanian S, Marshall-Clarke S, Hart CA, Cross A, et al. Microbial mannan inhibits bacterial killing by macrophages: a possible pathogenic mechanism for Crohn's disease. Gastroenterology 2007;133:1487–98.
[158] Wei Y, Chen T, Yang W, Li H, Fang C, Liu Q, et al. Detection of a novel antigen for Crohn's disease. Scand J Gastroenterol 2021:1–7.
[159] Jostins L, Ripke S, Weersma RK, Duerr RH, McGovern DP, Hui KY, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 2012;491:119–24.
[160] Cao Z, Sugimura N, Burgermeister E, Ebert MP, Zuo T, Lan P. The gut virome: a new microbiome component in health and disease. EBioMedicine 2022;81:104113.
[161] Ungaro F, Massimino L, D'Alessio S, Danese S. The gut virome in inflammatory bowel disease pathogenesis: from metagenomics to novel therapeutic approaches. United Eur Gastroenterol J 2019;7:999–1007.
[162] Federici S, Kredo-Russo S, Valdes-Mas R, Kviatcovsky D, Weinstock E, Matiuhin Y, et al. Targeted suppression of human IBD-associated gut microbiota commensals by phage consortia for treatment of intestinal inflammation. Cell 2022;185:2879–2898 e24.
[163] Gutierrez B, Domingo-Calap P. Phage therapy in gastrointestinal diseases. Microorganisms 2020;8:1420.
[164] Jansen D, Matthijnssens J. The emerging role of the gut virome in health and inflammatory bowel disease: challenges, covariates and a viral imbalance. Viruses 2023;15:173.
[165] Yanaka S, Yogo R, Kato K. Biophysical characterization of dynamic structures of immunoglobulin G. Biophys Rev 2020;12:637–45.
[166] Lidar M, Langevitz P, Barzilai O, Ram M, Porat-Katz BS, Bizzaro N, et al. Infectious serologies and autoantibodies in inflammatory bowel disease: insinuations at a true pathogenic role. Ann N Y Acad Sci 2009;1173:640–8.
[167] Lopes S, Andrade P, Conde S, Liberal R, Dias CC, Fernandes S, et al. Looking into enteric virome in patients with IBD: defining guilty or innocence ? Inflamm Bowel Dis 2017;23:1278–84.
[168] Hutt-Fletcher LM. EBV glycoproteins: where are we now? Future Virol 2015;10:1155–62.
[169] Friborg JT, Jarrett RF, Koch A, Garred P, Freeland JM, Andersen A, et al. Mannose-binding lectin genotypes and susceptibility to epstein-barr virus infection in infancy. Clin Vaccine Immunol 2010;17:1484–7.
[170] Kovacs M, Papp M, Lakatos PL, Jacobsen S, Nemes E, Polgar M, et al. Low mannose-binding lectin (MBL) is associated with paediatric inflammatory bowel diseases and ileal involvement in patients with Crohn disease. J Crohns Colitis 2013;7:134–41.
[171] Choteau L, Vasseur F, Lepretre F, Figeac M, Gower-Rousseau C, Dubuquoy L, et al. Polymorphisms in the mannose-binding lectin gene are associated with defective mannose-binding lectin functional activity in Crohn's disease patients. Sci Rep 2016;6:29636.
[172] Minamitani T, Yasui T, Ma Y, Zhou H, Okuzaki D, Tsai CY, et al. Evasion of affinity-based selection in germinal centers by Epstein-Barr virus LMP2A. Proc Natl Acad Sci U S A 2015;112:11612–7.
[173] Corouge M, Loridant S, Fradin C, Salleron J, Damiens S, Moragues MD, et al. Humoral immunity links *Candida albicans* infection and celiac disease. PloS One 2015;10:e0121776.
[174] Aaron L, Torsten M. *Candida albicans* in celiac disease: a wolf in sheep's clothing. Autoimmun Rev 2020;19:102621.
[175] Viitasalo L, Niemi L, Ashorn M, Ashorn S, Braun J, Huhtala H, et al. Early microbial markers of celiac disease. J Clin Gastroenterol 2014;48:620–4.
[176] Lang S, Duan Y, Liu J, Torralba MG, Kuelbs C, Ventura-Cots M, et al. Intestinal fungal dysbiosis and systemic immune response to fungi in patients with alcoholic hepatitis. Hepatology 2020;71:522–38.
[177] Goren I, Yahav L, Tulchinsky H, Dotan I. Serology of patients with ulcerative colitis after pouch surgery is more comparable with that of patients with Crohn's disease. Inflamm Bowel Dis 2015;21:2289–95.
[178] Leonardi I, Paramsothy S, Doron I, Semon A, Kaakoush NO, Clemente JC, et al. Fungal trans-kingdom dynamics linked to responsiveness to fecal microbiota transplantation (FMT) therapy in ulcerative colitis. Cell Host Microbe 2020;27:823–829 e3.
[179] Chen Q, Fan Y, Zhang B, Yan C, Chen Z, Wang L, et al. Specific fungi associated with response to capsulized fecal microbiota transplantation in patients with active ulcerative colitis. Front Cell Infect Microbiol 2022;12:1086885.
[180] Jena A, Dutta U, Shah J, Sharma V, Prasad KK, Shivaprakash RM, et al. Oral fluconazole therapy in patients with active ulcerative colitis who have detectable *Candida* in the stool : a double-blind randomized placebo-controlled trial. J Clin Gastroenterol 2022;56:705–11.
[181] Goren I, Godny L, Reshef L, Yanai H, Gophna U, Tulchinsky H, et al. Starch consumption may modify antiglycan antibodies and fecal fungal composition in patients with ileo-anal pouch. Inflamm Bowel Dis 2019;25:742–9.
[182] Margolis KG, Cryan JF, Mayer EA. The microbiota-gut-brain axis: from motility to mood. Gastroenterology 2021;160:1486–501.
[183] Seki D, Mayer M, Hausmann B, Pjevac P, Giordano V, Goeral K, et al. Aberrant gut-microbiota-immune-brain axis development in premature neonates with brain damage. Cell Host Microbe 2021;29:1558–1572.e6.
[184] Benito-Leon J, Laurence M. The role of fungi in the etiology of multiple sclerosis. Front Neurol 2017;8:535.
[185] Narunsky-Haziza L, Sepich-Poore GD, Livyatan I, Asraf O, Martino C, Nejman D, et al. Pan-cancer analyses reveal cancer-type-specific fungal ecologies and bacteriome interactions. Cell 2022;185:3789–3806 e17.

[186] Dohlman A, Klug J, Mesko M, Gao I, Lipkin S, Shen X, et al. A pan-cancer mycobiome analysis reveals fungal involvement in gastrointestinal and lung tumors. Cell 2022;185:3807–3822.e12.
[187] Zhu Y, Shi T, Lu X, Xu Z, Qu J, Zhang Z, et al. Fungal-induced glycolysis in macrophages promotes colon cancer by enhancing innate lymphoid cell secretion of IL-22. EMBO J 2021;40:e105320.
[188] Poulain D. *Candida albicans* and human health: a new concept in terms of the microbiota revolution ? J Mycol Med 2023;33:101378.
[189] Martini GR, Tikhonova E, Rosati E, DeCelie MB, Sievers LK, Tran F, et al. Selection of cross-reactive T cells by commensal and food-derived yeasts drives cytotoxic T (H)1 cell responses in Crohn's disease. Nat Med 2023;29:2602–14.
[190] Kusakabe T, Lin WY, Cheong JG, Singh G, Ravishankar A, Yeung ST, et al. Fungal microbiota sustains lasting immune activation of neutrophils and their progenitors in severe COVID-19. Nat Immunol 2023;24:1879–89.
[191] Underhill D, Braun J. Fungal microbiome in inflammatory bowel disease: a critical assessment. J Clin Invest 2022;132.
[192] Walker LJ, Aldhous MC, Drummond HE, Smith BR, Nimmo ER, Arnott ID, et al. Anti-*Saccharomyces cerevisiae* antibodies (ASCA) in Crohn's disease are associated with disease severity but not NOD2/CARD15 mutations. Clin Exp Immunol 2004;135:490–6.
[193] Tyler AD, Milgrom R, Xu W, Stempak JM, Steinhart AH, McLeod RS, et al. Antimicrobial antibodies are associated with a Crohn's disease-like phenotype after ileal pouch-anal anastomosis. Clin Gastroenterol Hepatol 2012;10:507–12 e1.
[194] Kotze LM, Nisihara RM, Utiyama SR, Kotze PG, Theiss PM, Olandoski M. Antibodies anti-*Saccharomyces cerevisiae* (ASCA) do not differentiate Crohn's disease from celiac disease. Arq Gastroenterol 2010;47:242–5.
[195] El Mouzan M, Al-Hussaini A, Fanelli B, Assiri A, AlSaleem B, Al Mofarreh M, et al. Fungal dysbiosis in children with celiac disease. Dig Dis Sci 2022;67:216–23.
[196] D'Argenio V, Casaburi G, Precone V, Pagliuca C, Colicchio R, Sarnataro D, et al. No change in the mucosal gut mycobioma is associated with celiac disease-specific microbiome alteration in adult patients. Am J Gastroenterol 2016;111:1659–61.
[197] Harnett J, Myers SP, Rolfe M. Significantly higher faecal counts of the yeasts *Candida* and *Saccharomyces* identified in people with coeliac disease. Gut Pathog 2017;9:26.
[198] Zhai B, Ola M, Rolling T, Tosini NL, Joshowitz S, Littmann ER, et al. High-resolution mycobiota analysis reveals dynamic intestinal translocation preceding invasive candidiasis. Nat Med 2020;26:59–64.
[199] Ardizzoni A, Sala A, Colombari B, Giva LB, Cermelli C, Peppoloni S, et al. Perinuclear anti-neutrophil cytoplasmic antibodies (pANCA) impair neutrophil candidacidal activity and are increased in the cellular fraction of vaginal samples from women with vulvovaginal candidiasis. J Fungi (Basel) 2020;6:225.
[200] Iliev ID, Leonardi I. Fungal dysbiosis: immunity and interactions at mucosal barriers. Nat Rev Immunol 2017;17:635–46.
[201] Zhou X, Zhang X, Yu J. Gut mycobiome in metabolic diseases: mechanisms and clinical implication. Biom J 2023:100625. https://doi.org/10.1016/j.bj.2023.100625.
[202] Fagoonee S, De Luca L, De Angelis C, Castelli A, Rizzetto M, Pellicano R. Anti-*Saccharomyces cerevisiae* as unusual antibodies in autoimmune hepatitis. Minerva Gastroenterol Dietol 2009;55:37–40.
[203] Lemoinne S, Kemgang A, Ben Belkacem K, Straube M, Jegou S, Corpechot C, et al. Fungi participate in the dysbiosis of gut microbiota in patients with primary sclerosing cholangitis. Gut 2020;69:92–102.
[204] Kreulen IAM, de Jonge WJ, van den Wijngaard RM, van Thiel IAM. *Candida* spp. in human intestinal health and disease: more than a gut feeling. Mycopathologia 2023;9.
[205] Papp M, Norman GL, Vitalis Z, Tornai I, Altorjay I, Foldi I, et al. Presence of anti-microbial antibodies in liver cirrhosis–a tell-tale sign of compromised immunity? PloS One 2010;5:e12957.
[206] Fairfield B, Schnabl B. Gut dysbiosis as a driver in alcohol-induced liver injury. JHEP Rep 2021;3:100220.
[207] Szczepanska M, Blicharz L, Nowaczyk J, Makowska K, Goldust M, Waskiel-Burnat A, et al. The role of the cutaneous mycobiome in atopic dermatitis. J Fungi (Basel) 2022;8.
[208] Assan F, Gottlieb J, Tubach F, Lebbah S, Guigue N, Hickman G, et al. Anti-*Saccharomyces cerevisiae* IgG and IgA antibodies are associated with systemic inflammation and advanced disease in hidradenitis suppurativa. J Allergy Clin Immunol 2020;146:452–455 e5.
[209] Reka P, Janka EA, Soltesz L, Szabo IL, Kapitany A, Dajnoki Z, et al. Chronic inflammatory intestinal disorders in hidradenitis suppurativa. Dermatology 2023;239:592–600.
[210] Ring HC, Thorsen J, Fuursted K, Bjarnsholt T, Bay L, Egeberg A, et al. Amplicon sequencing demonstrates comparable follicular mycobiomes in patients with hidradenitis suppurativa compared with healthy controls. J Eur Acad Dermatol Venereol 2022;36:e580–3.
[211] Condino AA, Hoffenberg EJ, Accurso F, Penvari C, Anthony M, Gralla J, et al. Frequency of ASCA seropositivity in children with cystic fibrosis. J Pediatr Gastroenterol Nutr 2005;41:23–6.
[212] Lachenal F, Nkana K, Nove-Josserand R, Fabien N, Durieu I. Prevalence and clinical significance of auto-antibodies in adults with cystic fibrosis. Eur Respir J 2009;34:1079–85.
[213] Hirche TO, Stein J, Hirche H, Hausmann J, Wagner TO, Behrens F, et al. Increased levels of anti-glycan antibodies in patients with cystic fibrosis. Eur J Med Res 2011;16:385–90.
[214] Francoise A, Hery-Arnaud G. The microbiome in cystic fibrosis pulmonary disease. Genes (Basel) 2020;11:536.
[215] Soret P, Vandenborght LE, Francis F, Coron N, Enaud R, Avalos M, et al. Mucofong investigation, respiratory mycobiome and suggestion of inter-kingdom network during acute pulmonary exacerbation in cystic fibrosis. Sci Rep 2020;10:3589.
[216] Gargano F, Guerrera G, Piras E, Serafini B, Di Paola M, Rizzetto L, et al. Proinflammatory mucosal-associated invariant CD8+ T cells react to gut flora yeasts and infiltrate multiple sclerosis brain. Front Immunol 2022;13:890298.
[217] Banati M, Csecsei P, Koszegi E, Nielsen HH, Suto G, Bors L, et al. Antibody response against gastrointestinal antigens in demyelinating diseases of the central nervous system. Eur J Neurol 2013;20:1492–5.
[218] Shah S, Locca A, Dorsett Y, Cantoni C, Ghezzi L, Lin Q, et al. Alterations of the gut mycobiome in patients with MS. EBioMedicine 2021;71:103557.
[219] Yadav M, Ali S, Shrode R, Shahi S, Jensen S, Hoang J, et al. Multiple sclerosis patients have an altered gut mycobiome and increased fungal to bacterial richness. PloS One 2022;17:e0264556.
[220] Monselise A, Weinberger A, Monselise Y, Fraser A, Sulkes J, Krause I. Anti-*Saccharomyces cerevisiae* antibodies in Behcet's disease–a familial study. Clin Exp Rheumatol 2006;24:S87–90.
[221] Krause I, Monselise Y, Milo G, Weinberger A. Anti-*Saccharomyces cerevisiae* antibodies–a novel serologic marker for Behcet's disease. Clin Exp Rheumatol 2002;20:S21–4.
[222] Fresko I, Ugurlu S, Ozbakir F, Celik A, Yurdakul S, Hamuryudan V, et al. Anti-*Saccharomyces cerevisiae* antibodies (ASCA) in Behcet's syndrome. Clin Exp Rheumatol 2005;23:S67–70.
[223] Rhee SH, Kim YB, Lee ES. Comparison of Behcet's disease and recurrent aphthous ulcer according to characteristics of gastrointestinal symptoms. J Korean Med Sci 2005;20:971–6.
[224] Cheng L, Li L, Liu C, Yan S, Li Y. Meta-analysis of anti-*Saccharomyces cerevisiae* antibodies as diagnostic markers of Behcet's disease with gastrointestinal involvement. BMJ Open 2020;10:e033880.
[225] Ishibashi K, Fukazawa R, Miura NN, Adachi Y, Ogawa S, Ohno N. Diagnostic potential of antibody titres against *Candida* cell wall beta-glucan in Kawasaki disease. Clin Exp Immunol 2014;177:161–7.
[226] Shor DB, Orbach H, Boaz M, Altman A, Anaya JM, Bizzaro N, et al. Gastrointestinal-associated autoantibodies in different autoimmune diseases. Am J Clin Exp Immunol 2012;1:49–55.
[227] Mankai A, Sakly W, Thabet Y, Achour A, Manoubi W, Ghedira I. Anti-*Saccharomyces cerevisiae* antibodies in patients with systemic lupus erythematosus. Rheumatol Int 2013;33:665–9.
[228] Yang P, Xu R, Chen F, Chen S, Khan A, Li L, et al. Fungal gut microbiota dysbiosis in systemic lupus erythematosus. Front Microbiol 2023;14:1149311.
[229] Mankai A, Thabet Y, Manoubi W, Achour A, Sakly W, Ghedira I. Anti-*Saccharomyces cerevisiae* antibodies are elevated in Graves' disease but not in Hashimoto's thyroiditis. Endocr Res 2013;38:98–104.
[230] Yazici D, Aydin SZ, Yavuz D, Tarcin O, Deyneli O, Direskeneli H, et al. Anti-*Saccharomyces cerevisiae* antibodies (ASCA) are elevated in autoimmune thyroid disease ASCA in autoimmune thyroid disease. Endocrine 2010;38:194–8.
[231] Alunno A, Bistoni O, Carubbi F, Valentini V, Cafaro G, Bartoloni E, et al. Prevalence and significance of anti-*Saccharomyces cerevisiae* antibodies in primary Sjogren's syndrome. Clin Exp Rheumatol 2018;36(Suppl. 112):73–9.
[232] Medeiros CCG, Dos Anjos Borges LG, Cherubini K, Salum FG, Medina da Silva R, de Figueiredo MAZ. Oral yeast colonization in patients with primary and secondary Sjogren's syndrome. Oral Dis 2018;24:1367–78.
[233] Andretta MA, Vieira TD, Nishiara R, Skare TL. Anti-*Saccharomyces cerevisiae* (ASCA) and anti-endomysial antibodies in spondyloarthritis. Rheumatol Int 2012;32:551–4.
[234] Maillet J, Ottaviani S, Tubach F, Roy C, Nicaise-Rolland P, Palazzo E, et al. Anti-*Saccharomyces cerevisiae* antibodies (ASCA) in spondyloarthritis: prevalence and associated phenotype. Joint Bone Spine 2016;83:665–8.
[235] Berthelot JM, Darrieutort-Laffite C, Trang C, Maugars Y, Le Goff B. Contribution of mycobiota to the pathogenesis of spondyloarthritis. Joint Bone Spine 2021;88:105245.
[236] Sakly W, Mankai A, Sakly N, Thabet Y, Achour A, Ghedira-Besbes L, et al. Anti-*Saccharomyces cerevisiae* antibodies are frequent in type 1 diabetes. Endocr Pathol 2010;21:108–14.
[237] Bandala-Sanchez E, Roth-Schulze AJ, Oakey H, Penno MAS, Bediaga NG, Naselli G, et al. Women with type 1 diabetes exhibit a progressive increase in gut *Saccharomyces cerevisiae* in pregnancy associated with evidence of gut inflammation. Diabetes Res Clin Pract 2022;184:109189.
[238] Bao L, Zhang Y, Zhang G, Jiang D, Yan D. Abnormal proliferation of gut mycobiota contributes to the aggravation of type 2 diabetes. Commun Biol 2023;6:226.
[239] Kvehaugen AS, Aasbrenn M, Farup PG. Anti-*Saccharomyces cerevisiae* antibodies (ASCA) are associated with body fat mass and systemic inflammation, but not with dietary yeast consumption: a cross-sectional study. BMC Obes 2017;4:28.
[240] Salamati S, Martins C, Kulseng B. Baker's yeast (*Saccharomyces cerevisiae*) antigen in obese and normal weight subjects. Clin Obes 2015;5:42–7.
[241] Cinemre H, Bilir C, Gokosmanoglu F, Kadakal F. Anti-*Saccharomyces cerevisiae* antibodies in acute myocardial infarction. J Invest Med 2007;55:444–9.
[242] Chen Y, Zhang LY, Fang Y, Li C, Xia DD, Zhang G, et al. Elevated serum anti-*Saccharomyces cerevisiae* antibody accompanied by gut mycobiota dysbiosis as a biomarker of diagnosis in patients with de novo Parkinson disease. Eur J Neurol 2023;11:3462–70.

[243] Cirstea MS, Sundvick K, Golz E, Yu AC, Boutin RCT, Kliger D, et al. The gut mycobiome in Parkinson's disease. J Parkinsons Dis 2021;11:153–8.

[244] Hughes HK, Ashwood P. Anti-*Candida albicans* IgG antibodies in children with autism spectrum disorders. Front Psych 2018;9:627.

[245] Andreo-Martinez P, Garcia-Martinez N, Quesada-Medina J, Sanchez-Samper EP, Martinez-Gonzalez AE. *Candida* spp. in the gut microbiota of people with autism: a systematic review. Rev Neurol 2019;68:1–6.

[246] Strati F, Cavalieri D, Albanese D, De Felice C, Donati C, Hayek J, et al. New evidences on the altered gut microbiota in autism spectrum disorders. Microbiome 2017;5:24.

[247] Zou R, Wang Y, Duan M, Guo M, Zhang Q, Zheng H. Dysbiosis of gut fungal microbiota in children with autism spectrum disorders. J Autism Dev Disord 2021;51:267–75.

[248] Dickerson F, Adamos M, Katsafanas E, Khushalani S, Origoni A, Savage C, et al. The association between immune markers and recent suicide attempts in patients with serious mental illness: a pilot study. Psychiatry Res 2017;255:8–12.

[249] Hao SR, Zhang Z, Zhou YY, Zhang X, Sun WJ, Yang Z, et al. Altered gut bacterial-fungal interkingdom networks in children and adolescents with depression. J Affect Disord 2023;332:64–71.

[250] Cihakova D, Eaton WW, Talor MV, Harkus UH, Demyanovich H, Rodriguez K, et al. Gut permeability and mimicry of the glutamate ionotropic receptor NMDA type subunit associated with protein 1 (GRINA) as potential mechanisms related to a subgroup of people with schizophrenia with elevated antigliadin antibodies (AGA IgG). Schizophr Res 2019;208:414–9.

[251] Severance EG, Alaedini A, Yang S, Halling M, Gressitt KL, Stallings CR, et al. Gastrointestinal inflammation and associated immune activation in schizophrenia. Schizophr Res 2012;138:48–53.

[252] Dzikowski M, Juchnowicz D, Dzikowska I, Rog J, Prochnicki M, Koziol M, et al. The differences between gluten sensitivity, intestinal biomarkers and immune biomarkers in patients with first-episode and chronic schizophrenia. J Clin Med 2020;9:3707.

[253] Yuan X, Li X, Kang Y, Pang L, Hei G, Zhang X, et al. Gut mycobiota dysbiosis in drug-naive, first-episode schizophrenia. Schizophr Res 2022;250:76–86.

[254] Severance EG, Gressitt KL, Stallings CR, Katsafanas E, Schweinfurth LA, Savage CLG, et al. Probiotic normalization of *Candida albicans* in schizophrenia: a randomized, placebo-controlled, longitudinal pilot study. Brain Behav Immun 2017;62:41–5.

[255] Severance EG, Gressitt KL, Yang S, Stallings CR, Origoni AE, Vaughan C, et al. Seroreactive marker for inflammatory bowel disease and associations with antibodies to dietary proteins in bipolar disorder. Bipolar Disord 2014;16:230–40.

[256] Sacchi MC, Tamiazzo S, Stobbione P, Agatea L, De Gaspari P, Stecca A, et al. SARS-CoV-2 infection as a trigger of autoimmune response. Clin Transl Sci 2021;14:898–907.

[257] Melayah S, Mankai A, Jemni M, Chaben AB, Ghozzi M, Ben Abdelkrim A, et al. Anti-*Saccharomyces cerevisiae* antibodies in patients with COVID-19. Arab J Gastroenterol 2022;23:241–5.

[258] Zuo T, Zhan H, Zhang F, Liu Q, Tso EYK, Lui GCY, et al. Alterations in fecal fungal microbiome of patients with COVID-19 during time of hospitalization until discharge. Gastroenterology 2020;159:1302–1310 e5.

[259] Aykut B, Pushalkar S, Chen R, Li Q, Abengozar R, Kim JI, et al. The fungal mycobiome promotes pancreatic oncogenesis via activation of MBL. Nature 2019;574:264–7.

[260] Fletcher AA, Kelly MS, Eckhoff AM, Allen PJ. Revisiting the intrinsic mycobiome in pancreatic cancer. Nature 2023;620:E1–6.

[261] Qin X, Gu Y, Liu T, Wang C, Zhong W, Wang B, et al. Gut mycobiome: a promising target for colorectal cancer. Biochim Biophys Acta Rev Cancer 2021;1875:188489.